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The multitude of cell types that constitute an adult human being contain the 
same genetic material. During development, a cell’s fate is decided by the initial gene 
expression. After acquiring its fate and position, this cellular identity is maintained by 
keeping some genes “on” and others “off”. If the maintenance mechanism fails, cells may 
lose their properties of proliferation, differentiation, adhesion or invasion when and 
where they should not(1, 2). Cancer is a result of defects in maintaining the cellular 
memory, causing cells to react inappropriately. The Polycomb Group (PcG) and trithorax 
Group (trxG) have been identified to keep the cellular memory and prevent changes in 
cell type specific transcription programs(1, 3). They are known to be involved in the 
process of histone modification, DNA methylation and chromatin transformation(4-10). 
To establish and maintain the cell identity, many pathways are involved in 
repressing specific sets of genes. From Drosophila to mammals, the genes of Polycomb 
group and trithorax group are widely conserved and they maintain the transcription 
patterns which are set in the first stages of embryonic life, and in the adulthood. TrxG and 
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PcG respectively regulate active and repressed genes related to development and cell 
cycle regulation. Both groups consist of multi-protein complexes which can modify 
chromatin and change its structure. As known, chromatin contains the imprints 
underlying the cellular memory and epigenetic inheritance. In Drosophila and mammals, 
both trxG and PcG bind to a specialized DNA element, Polycomb/trithorax Response 
Elements [PREs/TREs] to perform their epigenetic function(11, 12). 
By genetic screening, trxG and PcG were initially identified in Drosophila to 
establish and maintain homeobox (Hox) gene expression patterns(13-15). But the 
function of the trxG and PcG is not limited to regulate Hox gene expression(16). Further 
studies have shown that these proteins bind to thousands of chromosomal site in addition 
to the Hox genes(14, 15). In mammals, PcG genes expression exhibits a spatial and 
temporal pattern(15).  
PcG proteins appear to perform their functions by forming complexes. Two 
distinct Polycomb complexes have been characterized by immunoprecipitation, yeast-
two-hybrid and size-fractionation experiments in mammalian system (Figure 1.1).  BMI-
1, RING1, HPH1/2/3, and HPC1/2/3 (Psc, dRING, ph and Pc in Drosophila)(9, 10, 17) 
proteins constitute the Polycomb Repressive Complex 1 (PRC1) and EZH2, EED, SUZ12, 
RbAp46/48 and AEBP2 (E(z), Esc, Su(z)12, and RbAp48 in Drosophila)(9, 10, 15, 17) 
make the Polycomb Repressive Complex 2 (PRC2). The PRC2 was shown to physically 
associate with Yin Yang 1 (YY1, the human homolog of Pho in Drosophila)(18), which 
is the only known DNA binding protein of the Polycomb group, while all the others do 
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not have apparent DNA binding motifs(17). However, YY1 binding sites alone are not 
sufficient to alter the epigenetic pattern. It is shown that HDAC which is associated to 
EED(19, 20) is required for PRC2 to perform its function. EZH2/E(z) contains a 
conserved histone methyltransferase domain, SET domain, named after SU(var)3-9, E(z) 
and Trithorax which contain this enzymatic domain(17). Based on recent discoveries, a 
model is proposed to illustrate how Polycomb group complexes perform their function. 
At the beginning, the histone tails on the chromatin are acetylated and target genes are 
transcriptionally active. Once the cellular memory is disturbed, through the cell signaling 
pathway, PRC2 receives the signal from the cell signaling pathway and binds to a PRE. 
HDAC is then recruited to the PRE to deacetylate the histone tails, so that PRC2 can 
methylate the histone tails. This alters chromatin structure and enables PRC2 and HDAC 
to access the target gene promoters. Further, the histone tails on the gene promoters are 
deacetylated and then methylated. This methylation establishes a binding site for the N-
terminal chromodomain of PcG proteins so that PRC1 is recruited to the promoters of 
target genes to repress their expression by repressing transcription initiation(7, 21, 22). 
Accordingly, PRC2 is also called PRCi (initiation), and PRC1 is called PRCm 
(maintenance).  
Human E(z) homolog EZH2 was initially identified as a protein associated with 
proto-oncogene VAV in lymphoma. The gene of EZH2 maps to chromosome 7q35 and 
consists of 20 exons, encoding 746 amino acid residues(23). By yeast two-hybrid screen 
with EZH2, human Esc homolog EED was identified to interact with EZH2 in vitro,and 
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by co-IP, EZH2 and EED were confirmed to form a complex in vivo. Several studies 
demonstrated that the WD40 domains of EED are essential for this EZH2-EED complex, 
while the point mutants in the WD40 domain blocked the interaction between EZH2 and 
EED(9, 24-26). 
Another polycomb protein SUZ12 is also characterized as an essential 
component of PRC2 for its HMTase enzymatic activity. Several interacting partners of 
the EZH2-EED complex include SUZ12, RbAp48 and AEBP2, which were identified by 
isolating and characterizing the enzymatic complex which had high HMTase activity to 
histone H3(9). The reconstituted complex of EZH2, EED, SUZ12, RbAp48 and AEBP2 
can specifically methylate Histone H3 in vitro. GST pull down assays showed that EZH2 
strongly binds to EED, but not to other proteins; Besides EZH2, EED can also interact 
with SUZ12 and AEBP2, while RbAp48 strongly binds to SUZ12 and weakly to EED 
and AEBP2. In this complex, EZH2, EED and SUZ12 are required for the HMTase 
activity, and RbAp48 helps SUZ12 interact with EZH2-EED, and AEBP2 significantly 
increases the EZH2-EED-SUZ12 HMTase activity(9). 
In 2002, Kuzmichev et al. found that PRC2 exhibited HMTase activity and 
could specifically methylate H3K9 and H3K27(27). Furthermore they proved that the 
methylation of H3K27 provides a mark for PRC1 protein PC1 binding, therefore, PRC1 
is recruited to the targets. Generally the PRC2 protein EZH2 preferentially methylates 
Lysine 27 on histone 3 (H3K27)(8-10, 27). But under certain conditions, it can also 
methylate other substrates, such as H3K9 and H1BK26. Because EZH2 is the only known 
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histone methyltransferase which can tri-methylate H3K27, the level of tri-me-H3K27 is 
used as the marker of EZH2 enzymatic activity. Some groups also reported that there 
exist Polycomb Repressive Complex 3 (PRC3) and Polycomb Repressive Complex 4 
(PRC4) in cells(6, 27, 28). The human EED has four different isoforms due to alternate 
translation initiation sites from the same mRNA. All of these isoforms can associate to 
EZH2 to form different complexes and bind to their substrates. EED1 (the largest isoform) 
and EZH2 form PRC2 (~400-kDa complex) and methylate H3K27 in the presence of 
histone H1. EED3 and EED4 (the two shortest isoforms) can form PRC3 (~400-kDa 
complex) with EZH2, and methylate H3K27 when histone 1 is absent. EED2, SirT1, 
which specifically binds to EED2, and EZH2 form PRC4 (~1.5-MDa complex) and 
methylate K26 residue on H1B. 
Recently, another Polycomb group protein polycomblike (Pcl)/PHF1 has been 
identified to interact with the PRC2 complex in Drosophila and mammals(29, 30). By 
tandem affinity purification (TAP) strategy, Nekrasov et al. characterized a distinct PRC2 
complex containing Pcl from a transgenic Drosophila strain expressing a TAP-Pcl fusion 
protein. Like the regular PRC2 complex, the Pcl-PRC2 is a H3K27 specific HMTase. But 
the authors demonstrated that H3K27me3 levels are much lower in the Pcl-/- strains than 
in wild-type. By contrast, H3K27me1 and H3K27me2 levels are higher in Pcl-/- strains 
than in wild-type, suggesting that Pcl/PHD1 is required for generating high levels of tri-
methylated H3K27 and maintaining the Polycomb-repressed chromatin structure. 
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While the PRC2 complex possesses HMTase activity, the PRC1 complex has 
been identified to exhibit H2AK119 ubiquitin E3 ligase activity(7, 21, 22). The 
mammalian PRC1 H2AK119 ubiquitin E3 ligase complex consists of several PcG 
proteins and the RING2/RING1B protein is the catalytic subunit. The presence of BMI1, 
RING1/RING1A and PC3 significantly increases the complex ubiquitin E3 ligase activity 
of the complex, while RING1/RING1A with reconstituted N-terminus has ubiquitin E3 
ligase activity as well. Notably, BMI-1 interacts with RING1/RING1A, RING2/RING1B, 
PH2 and PC3, indicating that BMI-1 is important for the integrity of this complex. 
Although another Polycomb protein Mel-18 can replace BMI-1 and maintain the PRC1 
complex, Mel-18 could not stimulate the ubiquitin E3 ligase activity. Interestingly, 
knockdown of BMI-1 upregulates most late Hox genes and downregulates most early 
Hox genes(7). And knockdown of BMI-1 results in decreasing the H2A ubiquitination 
level and upregulating HoxC13. However, the binding of SUZ12 or the H3K27 
methylation level of the HoxC13 promoter is not affected by loss of BMI-1. Very 
importantly, when SUZ12 is knocked-down, the HoxC13 promoter H3K27 methylation 
level is decreased, and PRC1 could not bind to the promoter effectively, resulting a 
decrease of H2A ubiquitination. All these experiments provide a hierarchical recruitment 
model explaining how PRC2 and PRC1 exert their function to repress gene expression. 
PRC2 methylates H3K27 and provides a binding site for PRC1 recruitment through the 
specific recognition of the H3K27 methyl mark by the chromodomain of the Polycomb 
(Pc) protein. And then PRC1 can ubiquitinate H2A and turn off the gene expression. 
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Besides RING2/RING1B, another PRC1 protein Pc2 is reported to have SUMO 
E3 ligase activity(31). In 2003, Kagey et al. characterized that Pc2 is involved in the 
ubiquitination of the transcriptional repressor CtBP1 and CtBP2. Pc2 can interact with 
CtBP1 and CtBP2 via a PLDLS-like motif and recruit them to the PRC1. The sequence of 
Pc2 does not exhibit obvious similarity to any other known E3s. In 2005, the same group 
found that the C-terminal of Pc2 can act as a docking site for UBC9, a well known 
ubiquitin E2, and its substrates CtBP1 and CtBP2.  
Recently, Vire et al. reported that EZH2 can directly control DNA methylation, 
so that the two processes which can repress gene expression(4), Histone methylation and 
DNA methylation are connected, and this finding elucidates a mechanism by which 
Polycomb Group and DNA methyltransferases (DNMTs) work together to repress gene 
expression. The authors demonstrated that the complex pulled down with GST-EZH2 
possesses DNMT activity and this complex contains EZH2, DNMT1, DNMT3A and 
DNMT3B, and that the N-terminal H-1 and H-II domains of EZH2 are required for 
establishing and maintaining this complex. Furthermore, reciprocal co-
immunoprecipitation (co-IP) confirmed that DNMTs interact with PRC2, EZH2 and EED 
in vivo. Notably, similar to the effect of DNA methylation inhibitor 5’- aza-
deoxycytidine treatment, knock-down of EZH2, DNMT1, DNMT3A or DNMT3B 
markedly increases expression of their target genes, but not of the housekeeping genes. 
By ChIP in EZH2 RNAi cells, the authors demonstrated that EZH2 is essential for 
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DNMTs recruiting to the promoters of their targets, while RNA polymerase II could 
interact with the promoters and turn on the expression of target genes. 
Several papers reported that PcG proteins are involved in the de novo DNA 
methylation in cancers or cancer cell lines(32). By ChIP analyses, it is shown that genes 
with DNA methylation in cancer are marked with Polycomb proteins. Interestingly, many 
tumor suppressors are repressed by active de novo DNA methylation, and are pre-marked 
with H3K27 tri-methylation, indicating the mechanism by which EZH2 and PRC2 
promote cancer progression. In normal tissues, some tumor suppressors are marked with 
H3K27 tri-methylation, but not de novo DNA methylation, demonstrating that EZH2 
alone is not sufficient for DNA methylation, and several other components have to be 
recruited to methylate DNA to facilitate gene repression.  
Although EZH2 is required for DNA methylation, it is not required for 
maintaining DNA methylation and keeping the genes off. Some evidence demonstrated 
that knock-down of EZH2 can de-repress genes whose promoters are methylated, such as 
MYT1 and WNT1; But for the genes whose promoters are hypermethylated, such as 
MLH1, knockdown of EZH2 could not increase their expression, even though the H3K27 
trimethylation level is decreased because of the EZH2 knockdown(33). 
 
EZH2 and PcG in development 
In the Drosophila embryo, the segmental body plan is set in the first three and a 
half hours of development(34). Every segment has its own developmental fate 
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determined by a particular combination of homeotic gene products. Furthermore, 
maintenance of that decision is ensured by a particular combination set of homeotic 
proteins. The initial pattern of homeotic gene transcription in each segment is established 
by transcription factors encoded by the segmentation genes. After 5 to 7 hours of 
development, the transcriptional factors which control the initial development 
differentiation pattern decay and the relay is taken by the Polycomb (PcG) and trithorax 
(trxG) groups of proteins. PcG and trxG proteins have been identified in Drosophila to 
maintain the homeotic proteins and long-term gene silencing during development. 
However, E(z) and Esc are different from other PcG proteins because E(z) and Esc are 
required since early during development while the other PcG proteins appear to be 
required relatively late(34). Furthermore, E(z) and Esc are the most highly conserved PcG 
genes throughout evolution, since they are the only two PcG genes found in the C. 
elegans genome. 
In mammals, two homologues of E(z) have been characterized and named as 
EZH1 and EZH2. Sequence analysis shows that EZH1/2 have four conserved domains 
aligning to E(z)(24, 26), which are homologue domain I (H1 domain), homologue 
domain II (H2 domain), cysteine-rich domain and C-terminal SET domain. Biochemical 
study demonstrates that the C-terminal SET has histone methyltransferase activity and 
preferentially methylates Lysine 27 on Histone H3. The N-terminal H1 and H2 domains 
are protein-protein interaction domains. Yeast two-hybrid studies revealed that EZH2 can 
bind to the WD40 domains of EED through the H1 and H2 domains of EZH2. In addition, 
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EZH2 can bind to VAV through the H2 domain of EZH2, indicating that EZH2 plays a 
role in signal-dependent T-cell activation.  
In 2001, O’Carroll et al. reported that EZH2 is required for early mouse 
development and the homozygous EZH2 null mutations result in early lethality(34).  The 
authors found that at day 10.5, homozygous EZH2 null mutant embryos could not grow. 
And at day 7.5 the EZH2 mutant embryos were significantly smaller than their littermates. 
Some of the EZH2 mutant embryos were extremely growth retarded and the other 
displayed increased amounts of extraembryonic tissue along with growth retardation. The 
authors also reported development arrest and gastrulation failure in embryos from EZH2 
heterozygous intercrosses. The same group also reported that oocytes depleted of the 
maternal supply of EZH2 show severe growth retardation. And oocytes depleted of EZH2 
lacked methylated H3K27 and H3K9, while the level of methylated H3K4 is same as that 
of wild-type oocytes(35).  
PcG proteins are also reported to have a role in X chromosome inactivation (Xi) 
(36-39). In mammals, dose compensation is achieved by transcriptional silencing of one 
of the two X chromosomes in females. The process of Xi consists of multiple steps: 
choosing the active X chromosome, initiating the silence of Xi and maintaining the Xi 
throughout all the subsequent cell divisions. The non-coding RNA Xist (X inactivation 
specific transcript) is specifically transcribed from the Xic (X inactivation center) on the 
Xi, and covers the center of Xi in cis and triggers inactivation. Once Xist covers Xi, 
PRC2 is recruited and tri-methylates H3K27 on Xi, and PRC1 could be independently 
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recruited to Xist where it monoubiquitinates H2AK119. EED is important for protecting 
the inactive X-chromosome from differentiation-induced reactivation(36, 38, 40).  
 
PcG in stem cells 
Stem cells are a type of pluripotent cell with the ability to self-renew and 
differentiate to progenitors. To maintain the status of stem cells and control their fate, 
PcG proteins are employed for histone modifications, including histone methylation and 
ubiquitination, and DNA methylation. Studies have demonstrated that EZH2, EED, 
SUZ12 and RNF2 are essential for embryonic development(41, 42). EZH2, EED or 
RNF2 deficient mice are embryonic lethal and EZH2-null or EED-null embryonic stem 
(ES) cells could not be established. In hematopoietic stem cells (HSCs), both PRC1 and 
PRC2 are reported in regulating the self-renewal and differentiation of HSCs, consistent 
with the notion that PRC1 and PRC2 have to perform their functions sequentially to 
regulate gene expression(43). 
Recently, several groups have launched a global approach to identify the target 
loci for binding of PcG proteins by genome-wide mapping in human fibroblasts, human 
ES cells, mouse ES cells or Drosophila(44-48). All of these studies demonstrated that 
PcG proteins directly repress a large number of regulators that are involved in early 
developmental steps, a wide variety of developmental processes, and cell differentiation. 
PcG proteins also regulate genes in a variety of signaling pathways including WNT, FGF 
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(Fibroblast Growth Factor), BMP (Bone Morphogenic Protein) and TGFβ (Transforming 
Growth Factor β). These signals are required for linage differentiation and are associated 
with cancer progression. These studies of PcG in ES cells give clues about how 
dysregulation of PcG proteins perform their function to promote tumorigenesis. 
 
Polycomb group and Cancer 
Multiple lines of evidence show that PcG proteins are dysregulated and play 
important roles in cancer progression (Table 1.1) 
The PRC1 protein BMI-1 was the first reported PcG protein to be associated 
with cancer development. BMI-1 is the human homologue of Drosophila Psc and has 
been reported to promote the generation of B- and T-cell lymphomas by collaborating 
with c-MYC. One proposed mechanism suggested that BMI-1 may inhibit c-MYC 
induced apoptosis via INK4A/ARF and regulate cell proliferation and senescence (49, 
50). INK4A and ARF play a role to restrict cellular proliferation in response to aberrant 
mitogenic signaling. INK4A is a cyclin-dependent kinase inhibitor and it can activate the 
RB pathway. ARF can inhibit MDM2 function to induce p53. In many types of tumors, 
the INK4A/ARF locus is found to be mutated, deleted or epigenetically silenced.  
Interestingly, when neuroblastoma (NB) and other cancerous human cells were 
treated with siRNA against BMI-1, cells grew poorly and had elevated levels of apoptosis 
within three days after transfection, whereas neurons and other normal human cells did 
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not show this phenomenon. Furthermore, RNAi mediated suppression of BMI-1 led to 
significant cell death in human embryonic carcinoma stem cells, but not in normal 
embryonic stem cells, indicating that BMI-1 may perform as a cancer stem cell factor to 
regulate the growth and survival of cancer(51). 
Another PRC1 protein RING1 was also shown to interact with BMI-1 and 
overexpression of RING1 represses engrailed and increases expression of c-JUN and c-
FOS. Furthermore, RING1 induces anchorage-independent growth of Rat1a and NIH3T3 
cells with overexpression of RING1 can form tumors in nude mice(52-54).  
 
EZH2 is a biomarker of metastatic prostate cancer. 
Among epithelial derived tumors, EZH2 was first observed to be significantly 
associated with metastatic prostate cancer. Along with MTA-1, HPN, PIM1 and several 
other genes, EZH2 is overexpressed in hormone-refractory, metastatic prostate cancer, 
and is a biomarker of prostate metastases(55). Through gene expression profiles of 
benign prostate, prostate cancer (PCa) and metastatic prostate cancer, EZH2 was one of 
the top genes upregulated in metastatic prostate cancer(56-62). Importantly, the EZH2 
protein level was significantly increased in metastatic prostate cancer compared to PCA 
or benign prostate, while EED levels were not altered in metastatic prostate cancer(57). 
To determine the expression of EZH2 protein levels in situ, a wide spectrum of cancer 
tissues was evaluated in a tissue microarray format. EZH2 antibodies mainly stained the 
nucleus since EZH2 has a nuclear localization sequence. And the intensity of EZH2 
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staining increased from benign, prostatic atrophy, prostatic intraepithelial neoplasia, 
clinically localized prostate cancer, to metastatic prostate cancer. Furthermore, expression 
of EZH2 was significantly associated with clinical failure. However, EZH2 protein was 
not correlated to Gleason score, tumor stage or surgical margin status.  
EZH2 is essential for cell proliferation. When EZH2 was knocked-down by 
RNA interference in the prostate cell lines PC3 and RWPE and the osteosarcoma cell line 
U2OS(57, 63), cell proliferation was significantly inhibited, but EZH2 RNAi did not 
induce apoptosis.  And notably, EZH2 depleted cells showed cell-cycle arrest in the 
G2/M phase indicating that EZH2 plays a role in cell proliferation by mitigating G2/M 
transition. 
Importantly, ectopic expression of EZH2 does not upregulate any other genes in 
prostate or breast cells and the C-terminal SET domain is essential for EZH2 to perform 
its histone methyltransferase activity. Notably the HDAC inhibitor trichostatin A can 
completely block EZH2 function, suggesting that HDAC activity is required for EZH2 
and PRC2 to exert their functions(57). 
To explain why EZH2 is overexpressed in prostate metastases, the genomic 
region of EZH2 has been analyzed by array comparatively genomic hybridization (aCGH) 
and fluorescence in situ hybridization (FISH) in prostate cancer cell lines and clinical 
prostate tumors. It is reported that the number of EZH2 copies is increased in prostate 
cancer cell lines DU145, PC-3, 22Rv1 and LNCaP, and also in the xenograft cell line 
LuCaP41. Importantly, EZH2 is amplified in 26% of hormone-naïve prostate cancer and 
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54% of hormone-refractory prostate cancer samples, suggesting that EZH2 gene 
amplification might result in overexpression of EZH2 in prostate metastases(59, 61).  
Interestingly, EZH2 was observed to be highly over expressed in prostate 
carcinoma metastasis precursor cells with PRC1 protein BMI1(64). By quantitative 
immunofluorescence colocalization analysis, Berezovska et al. demonstrated a marked 
enrichment of the population of circulating human prostate carcinoma metastasis 
precursor cells with dual-positive high-BMI1/EZH2-expressing cells. RNA interference 
against BMI1 or EZH2 showed that high levels of BMI1 and EZH2 help prostate cancer 
cells resist apoptosis that is induced in cells of epithelial origin in response to attachment 
deprivation. Importantly, depletion of BMI1 or EZH2 in prostate carcinoma metastasis 
precursor cells diminishes their tumorigenic, metastatic and proliferation potential when 
injected into mice.  
Recently, a Polycomb repression signature in metastatic prostate cancer has 
been revealed to predict cancer outcome(65). To investigate the role of PRC2 in 
metastatic prostate cancer, Yu et al. performed ChIP-on-chip by anti-SUZ12 and anti-
H3K27me3 antibodies in late-stage, aggressive prostate cancer tissues. Genome-wide 
location analysis showed that there is a strong overlap between the genomic sites 
occupied by SUZ12 and H3K27me3 in metastatic prostate cancer and prostate cancer cell 
lines. Oncomine Molecular Concept Map (MCM) analysis showed that H3K27 occupied 
genes are consistent with genes down-regulated in prostate, breast and lung cancers, since 
EZH2 is upregulated in aggressive cancers and PRC2 are transcriptional repressors. 
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Importantly, there is a strong link between H3K27 occupied genes in prostate metastases 
and H3K27me3-, SUZ12-, or EED-occupied genes in embryonic stem cells, which 
indicates that the function of PRC2 to control stem cell pluripotency and differentiation is 
essential for prostate cancer progression. In addition, the Polycomb repression signature 
is able to successfully predict the clinical outcome of prostate and even breast cancer 
patients.  
Among the genes regulated by EZH2 in prostate cancers, ADRB2, a G-protein 
coupled receptor (GPCR) of the β-adrenergic signal pathway, has been characterized as 
one of the key proteins(66). By down-regulation of the key target genes, EZH2 promotes 
cell anchorage-independent growth, migration and invasion potential, and then induces 
prostate metastasis. By cDNA microarray, ADRB2 was identified as a target of EZH2. 
Overexpression of EZH2 can repress ADRB2 at both transcript and protein levels, and 
the recently discovered EZH2 inhibitor, DZNep(67), can prevent ADRB2 repression by 
EZH2. Notably, the promoter of ADRB2 is occupied by the PRC2 complex and 
H3K27me3. However the dominant negative mutant of EZH2 (EZH2∆SET) does not 
bind to the ARRB2 promoter. Also, the HDAC inhibitor, SAHA, blocks PRC2 to access 
the ADRB2 promoter, consistent with the mechanism that HDAC activity is required for 
PRC2 to perform its transcriptional repression. Interestingly, ADRB2 expression is low in 
prostate cancer cell lines which have high EZH2 levels. Stable prostate cell line clones of 
EZH2 knock down showed a marked increase in ADRB2 expression. Importantly, co-
expression of ADRB2 decreases the EZH2-mediated epithelial cell invasion, while an 
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antagonist of ADRB2 makes the non-invasive epithelial cells invasive. Furthermore, 
ADRB2 antagonist treated or stable ADRB2 knock-down non-invasive epithelial cells 
exhibit a mesenchymal phenotype with fibroblast-like shape, and the epithelial-
mesenchymal transition (EMT) markers such as Vimentin, N-cadherin are increased 
while ADRB2 activity is inhibited or expression is decreased. Similar to the EZH2 stable 
knock-down, the agonist of ADRB2 inhibits tumor growth in a xenograft mouse model. 
All these clues indicate that EZH2 promotes anchorage-independent cell growth, 
migration, invasion and tumorigenesis through ADRB2 and other signaling pathways.  
Another tumor suppressor, prostatic secretory protein 94 amino acids (PSP94), 
has been characterized as a target of EZH2(68). There is an inverse correlation between 
EZH2 and PSP94 in advanced, hormone-refractory prostate cancer. The promoter of 
MSMB which encodes PSP94 is occupied by PRC2 and H3K27me3. Furthermore, 
overexpression of EZH2 represses MSMB expression while EZH2 RNAi increases 
MSMB mRNA level. Importantly, both the HDAC inhibitor TSA and the DNA 
methyltransferase inhibitor 5’-aza-deoxycytidine de-repress MSMB from the repression 
of EZH2.  
Another potent growth inhibitor, the human DOC-2/DAB2 interactive protein 
(hDAB2IP, also called ASK-interacting protein 1 (AIP1)), is reported as a target of EZH2 
in prostate cancer(69). Similar to ADRB2 and PSP94, there is a negative correlation 
between EZH2 and hDAB2IP in normal prostate epithelium, primary prostate cancer 
cells and metastatic prostate cancer cell lines. Knock-down of EZH2 increases hDAB2IP 
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mRNA, while overexpression of EZH2 represses hDAB2IP promoter activity and protein 
level. Importantly, EZH2 and the PRC2 complex bind to the promoter of hDAB2IP and 
overexpression of EZH2 leads to H3K27 tri-methylation of hDAB2IP promoters to 
repress hDAB2IP expression. 
EZH2 is usually located in nucleus since it has a nuclear localization signal 
(NLS), but it is reported that in ex vivo isolated thymocytes, a fraction of EZH2 is  also 
present in cytoplasm(70, 71). Later, Bryant et al. reported that EZH2 is overexpressed in 
both nucleus and cytoplasm in malignant prostate tissues comparing to normal prostate 
tissues(72). Interestingly, EZH2 can form a functional histone methyltransferase complex 
with EED and SUZ12 in the cytoplasm, and this complex can methylate H3K27 when 
incubated with nucleosome in vitro. Also, the cytosolic PRC2 complex associates with 
VAV1 indicating this cytosolic PRC2 complex may play a role in VAV-dependent 
pathways, such as T cell antigen receptor (TCR) mediated actin polymerization. Similarly, 
knock-down of EZH2 in prostate cancer cells increases polarized actin (F-actin). This 
function of EZH2 may help illuminate the mechanism by which EZH2 promotes prostate 
cancer invasion and metastasis. 
 
EZH2 is a biomarker of aggressive breast cancer. 
Every year, over 180,000 American women are diagnosed with breast cancer. 
Although most of them will receive some kind of treatment such as chemotherapy and 
radiotherapy, mortality for those 20% of patients with recurrences and or metastases is 
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nearly 100%. Given the high mortality rate, the main challenge is to find some good 
prognostic factors regulating breast cancer development and progression that will 
facilitate early diagnosis of breast cancer with high specificity (73, 74).  
Based on our previous work characterizing EZH2 in prostate cancer(55, 57), our 
group investigated the role of EZH2 in breast cancer and demonstrated that EZH2 is 
elevated at both the transcript and protein levels in invasive and metastatic breast cancer 
when compared to normal breast tissues(75). Immunohistochemical analyses performed 
on a spectrum of breast cancer tissues demonstrated that high EZH2 levels were strongly 
associated with poor clinical outcome in patients. Higher EZH2 protein levels were 
associated with a shorter disease-free interval after initial surgical treatment, lower 
overall survival, and a high probability of disease-specific death (i.e. death due to breast 
cancer). Also, high EZH2 expression was associated with disease-specific death in 
patients with lymph node-negative disease, but not in patients with positive lymph nodes. 
EZH2 expression was associated with disease-specific survival in patients with stage I 
and II disease, but not in patients with advanced stage (stages III and IV). Kaplan–Meier 
analysis showed that EZH2 levels were strongly associated with bad outcome in both ER-
positive and -negative invasive carcinomas suggesting that EZH2 has prognostic utility 
independent of ER status. 
Importantly, overexpression of EZH2 could increase HDAC enzymatic activity. 
Also overexpression of EZH2, but not the dominant negative mutant of EZH2, 
EZH2∆SET, promotes anchorage-independent growth in epithelial cells. Furthermore, 
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three different in vitro or in vivo invasion assays have been employed showing that EZH2 
overexpression increases the invasion potential of breast epithelial cells, while 
EZH2∆SET could not. Notably, the HDAC inhibitors TSA and SAHA could attenuate 
invasion induced by EZH2. All of those clues indicate that both HDAC and HMTase 
activity are essential for the PRC complex to exert its function to regulate gene 
expression. 
However, the expression patterns of PRC1 and PRC2 are different in various 
stages of tumor progression. The PRC1 complex expression is always high in normal 
breast tissues, preinvasive lesions and invasive breast carcinomas, which is consistent 
with the function of PRC1 to maintain the gene expression pattern. But in normal breast 
tissues, EZH2 and EED are rarely detectable except in the cycling cells. In the 
preinvasive lesions, EZH2 is still rarely detectable in the well-differentiated ductal 
carcinoma in situ (DCIS), while in poorly differentiated DCIS, EZH2 expression is 
significantly increased and detectable. EZH2 expression is highest in poorly 
differentiated invasive breast carcinomas but is still undetectable in well-differentiated 
invasive carcinomas. Interestingly, EZH2 expression is significantly higher in patients 
with BRCA1 heterozygous mutation who have much higher risk of developing breast 
cancer than in control patients. Also histologically normal breast tissues from patients 
who developed cancer had significant up-regulation of EZH2 when compared with 
tissues from patients who did not develop cancer. All of these evidences demonstrated 
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that EZH2 expression is associated with cancer progression and is a biomarker of the 
precancerous state in morphologically normal tissues. 
To investigate the mechanism by which EZH2 promotes cell transformation and 
invasion, we did cDNA microarray analyses and ChIP-on-chip measurements in samples 
with EZH2 overexpression or knock-down samples. Among the list of EZH2 regulated 
genes, the tumor suppressor E-cadherin appears to be one of the key targets. Our previous 
work in prostate cancer demonstrated that there is an inverse correlation between EZH2 
and E-cadherin in prostate cancer progression(76). In normal prostate and breast samples, 
EZH2 expression is low while E-cadherin expression is very high and there is good E-
cadherin membrane staining by immunohistochemical analysis or immunofluorescence 
microscopy. In aggressive prostate and breast cancers, however, EZH2 expression is 
increased while E-cadherin expression is repressed. A similar pattern is observed in 
normal and cancerous cell lines prostate or breast. Importantly, When EZH2 is 
ectopically overexpressed in prostate and breast epithelial cells E-cadherin is repressed at 
both the transcript and protein levels. Also, this EZH2 mediated repression could be 
inhibited by the HDAC inhibitor SAHA. Furthermore, co-expression of E-cadherin can 
attenuate EZH2-mediated invasion in prostate and breast epithelial cells, indicating that 
E-cadherin is an important target of EZH2 in cancer progression. With an E-cadherin 
promoter activity assay, we demonstrated that the E-boxes of A and C are essential for 
EZH2 to repress E-cadherin. The promoter of E-cadherin is occupied by the PRC2 
complex and shows H3K27 tri-methylation by PRC2 when EZH2 is overexpressed. In the 
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presence of the HDAC inhibitor SAHA, PRC2 could not bind to the E-cadherin promoter, 
H3K27 tri-methylation was absent, and the acetylation level of histone H3 was increased, 
indicating that E-cadherin expression is activated by SAHA. This work is consistent with 
the finding that in ES cells, PRC2 occupies the promoter of E-cadherin and represses its 
expression, indicating that the function of PRC2 to control stem cell pluripotency and 
differentiation is important for cancer progression. 
Besides repressing tumor suppressors, EZH2 also represses genes associated 
with DNA repairs(77, 78). In mammals, hampered Double-strand break (DSB) repair 
could lead to chromosomal abnormalities resulting in cell death or cancer. To repair the 
DSB, the homologous recombinase RAD51 and its paralogs are required. Multiple 
studies demonstrate that RAD51 paralogs are important for maintaining chromosomal 
integrity in the early and late stage of homologous recombination (HR). Our group has 
reported that overexpression of EZH2 significantly downregulates the RAD51 paralogs, 
RAD51L1, RAD51L2, RAD51L3, XRCC2 AND XRCC3, at both the transcript and 
protein levels. Those RAD51 paralogs are required for the formation of DNA damage–
induced RAD51 repair focus. Once any of them are mutated, RAD51 foci formation is 
significantly attenuated. We demonstrated that overexpression of EZH2 in breast 
epithelial cells markedly decreases RAD51 foci formation after induction of DSB by 
etoposide, indicating that HR repair is less effective in EZH2 overexpressing cell than in 
control cells. Furthermore, overexpression of EZH2 significantly decreases the survival, 
clonogenic capacity and colony-forming ability of breast epithelial or cancer cell lines. 
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All of this evidence suggests that EZH2 play an important role in the HR mechanism of 
DNA repair which may cause aneuploidy in breast epithelial cells. 
As a component of a transcriptional repressive complex, EZH2 mainly performs 
its function to repress tumor suppressors and promote cancer progression. But studies in 
Drosophila indicate that EZH2 may have function as a transcriptional activator to 
increase the expression of some genes. Recently some evidence shows that in breast 
cancer cells, where EZH2 increases levels of the oncogene c-Myc and cyclin-D1, known 
estrogen receptor (ER) and WNT targets, which are important in the regulation of cell 
cycle and proliferation(79). In ER positive cell lines MCF7 and MDA-MB-231, 
overexpression of EZH2 significantly enhanced the promoter activities of c-Myc and 
cyclin D1. Notably, this enhancement was dependent on ER since ER antagonist 
ICI182780 abolished the EZH2 mediated enhancement of promoter activity. Interestingly 
the homolog EZH1 did not regulate c-Myc and cyclin D1 promoter activities, 
demonstrating the specificity of EZH2. Furthermore, GST pull-down and reciprocal co-
immunoprecipitation (co-IP) assays demonstrated that ERα, EZH2 and β-catenin form a 
functional complex in vitro and in vivo. ChIP assay analysis confirmed that this complex 
is recruited to the promoters of c-Myc and cyclin D1. However, neither ERβ nor AR 
interacted with EZH2, indicating the specificity of ERα for this complex. The study of 
mutants of EZH2 showed that the homolog domains 1 and 2 are essential for this ERα, 
EZH2 and β-catenin complex to activate c-Myc and cyclin D1 promoter activity, while 
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the cys-rich domain and SET domain are not required for maintaining this complex or for 
mediating its function.  
Besides c-Myc and cyclin D1, EZH2 also activates cyclin A2(80). Unlike the 
mechanism of increasing c-Myc and cyclin D1, EZH2 up-regulates cyclin A2 indirectly. 
It was showed that EZH2 can bind to pRb2/p130 and repress its function, which in turn 
de-repress the expression of cyclin A2. Like the other two members of the Rb family, 
pRb/p105 and p107, pRb2/p130 functions as a transcriptional repressor of cell cycle 
promoting genes. HDAC1 is required for E2F-Rb complex to perform its function to 
repress the expression of its targets. As another well-known transcriptional repressor, 
EZH2 and its complex also interact with HDAC1 to perform their function. Some 
evidence showed that EZH2 may interact with HDAC1 and pRb2/p130 subsequently 
interfering with pRb2/p130 mediated repression. Reciprocal co-IP demonstrated that 
EZH2 and pRb2/p130 form a complex in vitro and in vivo. While overexpression of 
pRb2/P130 alone represses cyclin A2 promoter activity, co-expression of EZH2 abolishes 
the repression induced by pRb2/p130 by inhibiting pRb2/p130-HDAC1 binding to the 
promoter of cyclin A2. Furthermore the C-terminus of pRb2/p130 is important for 
forming the complex containing EZH2-HDAC-pRb2/p130. These two studies provide 
mechanisms through which EZH2 may act as a transcriptional activator rather than a 
repressor. 
 
EZH2 in other cancers 
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The transcriptional repressor EZH2 is also involved in other types of cancer 
progression, such as bladder(81-85), gastric(86), lung(87), liver (88) and leukemia(58, 89) 
besides prostate and breast. 
In 2005, Sudo et al. reported that EZH2 expression is significantly higher in 
human liver cancer cell lines and tissue specimens compared to normal sections(88). 
They also noted that the invasion potential to the portal vein of cancer cells is 
significantly higher in the group with high EZH2 expression than in the low EZH2 
category. Chen et al. demonstrated that knock-down of EZH2 markedly inhibits the 
growth of hepatocellular carcinoma (HCC) cells and reduces the tumorigenicity of HCC 
cells in the nude xenograft mice. Importantly, growth of established HCC tumors could 
be significantly reduced by treatment with EZH2 shRNA or siRNA suggesting EZH2 
may be a potential therapy target. The authors reported that EZH2 knock-down inhibits 
HCC cell growth by repressing OP-18/stathmin. 
In bladder and gastric cancers(83-86), EZH2 is increased at both the transcript 
and protein levels in cancer cell lines and cancer tissue specimens relative to normal 
controls. EZH2 expression is also associated with cell invasion in bladder cancer. 
Importantly, Kaplan-Meier analysis indicated that patients with high level of EZH2 had a 
worse prognosis than those with lower levels. 
 
The regulation of EZH2 in cancer 
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Elucidation of the mechanism of EZH2 dysregulation in cancer will help in 
understanding the biology of this protein in cancer progression. In 2003, Bracken et al. 
identified E2F1-3 regulation of EZH2 and PRC2 in cancer cells(63). Activation of E2F1-
3 can markedly increase EZH2, EED and SUZ12 expression levels, while overexpression 
of pRB and p16, the upstream regulators which can repress the activity of E2Fs, decrease 
expression of EZH2 and EED. Mouse embryonic fibroblasts (MEFs) with a pRb-/- 
genotype had elevated levels of EZH2 and EED. Furthermore, loss of p16 leads to 
overexpression of PRC2 at the transcript and protein levels, and induces the DNA 
hypermethylation of PRC2 targets. Also, EZH2 is reported to be down-regulated in 
senescent cells by p53 activation(90) and this downregulation is dependent on p21/waf1, 
which can inactivate E2F pathway. By ChIP and promoter activity assays, it was shown 
that E2F1-3 can directly bind to the promoters of EZH2 and EED and upregulate their 
expression. However, E2F1-3 cannot regulate the activity of the EZH2 promoter without 
potential E2F binding sites. Since E2F3 is amplified and overexpressed in prostate and 
bladder cancers, all of the evidence provides a mechanism to explain the upregulation of 
EZH2 during cancer progression. 
Interestingly, BMI-1 is also reported as a target of E2F1-3(91), but not of E2F4 
or E2F5. Promoter assays  and ChIP studies indicated that E2F1-3 directly binds to and 
increases wild-type BMI-1 promoter activity. This does not occur with a mutated 
promoter in which the potential E2F binding site is mutated. This finding is consistent 
with the mechanism by which PRC2 and PRC1 perform their function together to bring 
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about gene repression. Figure 1.2 proposes a possible pathway of how PcG proteins are 
regulated and exert their function in cancer. 
Another possible mechanism of EZH2 overexpression in cancers could be due 
to gene amplification (58). Copy number variation of EZH2 (>4 copies) is known to 
occur in multiple cancers, including bladder (2/7), breast (9/65), colon (5/22), 
glioblastoma (2/14), larynx (5/11), lung (3/15), lymphoma (1/11), sarcoma (1/9), stomach 
(2/14), testis (3/11) and late stage of prostate cancer (33/125 of hormone native prostate 
cancer and 25/46 of hormone refractory prostate cancer). 
EZH2 may have a cytoplasmic function when it loses its nuclear localization 
signal (70-72) and this mutant protein could promote cancer development. In several cell 
types including late stage of prostate cancer, this EZH2 mutant can form a PRC2 complex 
with HMTase activity in the cytosol and promote TCR/PDGF-induced actin 
polymerization and induce tumorigenesis.  
Another report suggests protein phosphorylation as a possible mechanism to 
regulate the activity of EZH2. In 2005, Cha et al. showed that EZH2 is downstream of the 
PI3K-Akt signaling pathway, which is involved in cell proliferation, motility and 
survival(92). The authors found an inverse correlation between activated Akt and the 
level of H3K27 tri-methylation.  An inhibitor of the PI3K-Akt pathway, LY294002, was 
able to block phosphorylated Akt mediated repression of H3K27 tri-methylation. By co-
IP, the authors demonstrated that constitutively activated Akt interacted with EZH2 or 
EZH2∆SET and that Akt could phosphorylate the Ser21 of EZH2. Interestingly, this 
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phosphorylated EZH2 does not affect the formation of a PRC2 complex, but it does 
reduce its affinity to H3K27. Hence, this phosphorylated EZH2 has less HMTase activity. 
Therefore, activated Akt could repress EZH2 activity, decrease the level of H3K27 tri-
methylation and increase the expression of EZH2 targets. They also showed that the 
S21A-EZH2 mutant has much higher HMTase activity and a stronger interaction with 
chromatin than does wild type EZH2. This S21A-EZH2 significantly repressed EZH2 
target expression. This finding provides a possible method to repress EZH2 function for 
cancer therapy. 
Recently, a novel mechanism that may dysregulate PRC2 in cancer progression 
was identified. Li et al. reported that in endometrial stromal tumors there is a series of 
rearrangements of DNA within the genes coding for the PRC2 complex (93). The authors 
discovered that in three primary endometrial stromal sarcomas (ESSs) cell lines, there 
exists a t(7;17) translocation and the C-terminus of SUZ12 is fused to the N-terminus of 
JAZF1. Importantly, this fusion protein can restore EZH2 activity and help methylate 
H3K27. Since PRC2 expression is usually very low in normal differentiated cells, this 
phenomenon of a fusion protein demonstrates a novel mechanism to dysregulate PRC2 
and promote cancerigenesis. 
 
EZH2 as a target for cancer therapy  
The enzymatic activity (HMTase) and its function as an epigenetic repressor 
along with its established role in cancer progression, makes EZH2 an attractive target for 
29 
cancer therapy. We and others have shown that knock-down of EZH2 inhibits cancer cell 
growth, motility, invasion and tumorigenesis. Small interfereing RNA against EZH2 
reduced EZH2 expression in several cancer cell lines, significantly inhibited cell 
proliferation and the cells were arrested at the G2/M phase (57, 63, 66). In addition, the 
EZH2 knock down cells did not retain their invasive potential when injected into mice. 
This was apparent from the lack in tumor formation(66). Interestingly, tumor size was 
decreased and growth inhibited in established tumors in mice when an shRNA against 
EZH2 was delivered. This indicates the promise that EZH2 holds as a candidate for 
cancer therapy(94). 
Synthetic peptide fragments of EZH2 were able to stimulate peripheral blood 
mononuclear cells (PBMCs) and produce EZH2-specific cytotoxic T lymphocytes 
(CTLs). Interestingly, those EZH2-specific CTLs can generate IgG against EZH2 and are 
toxic to HLA-A24 positive cells(95). This finding provides an alternative approach to 
inhibit EZH2 function in cancer progression. 
 EZH2 and PRC2 mediate their function as a complex with HDAC and our 
group demonstrated that the HDAC inhibitors TSA and SAHA can abrogate EZH2’s 
function in H3K27 methylation, transcriptional repression and cell invasion(57, 66, 75). 
However, these agents are global inhibitors and regulate EZH2 indirectly and might 
produce undesirable side effects from a clinical standpoint. Now many groups are 
working on small molecule inhibitor screening for EZH2 based on wide range of 
approaches. Recently, Tan et al. has discovered that S-adenosylhomocysteine hydrolase 
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inhibitor 3-Deazaneplanocin A (DZNep) can deplete EZH2, EED and SUZ12 protein 
levels, inhibiting H3K27 methylation(67). The authors showed that following depletion 
of PRC2 by DZNep, RNA polymerase II can occupy the promoters of PRC2 targets and 
transcriptionally activate them. Interestingly, DZNep can re-activate some 
hypermethylated genes where 5’-Aza-dC and TSA failed, suggesting that DZNep could 
cause DNA demethylation. However, PRC2 repression by DZNep was not dependent on 
this function. In addition, DZNep could induce apoptosis specifically in cancer but not in 
normal cells. Hence is a compound that holds high promise for further characterization.  
 
31 






















PRC1 Stabilization of PRC1 complex 
 







Target of E2F1-3;  
Immortalize normal 
human oral keratinocytes;
Promote the generation of 
B- and T-cell lymphomas 
with c-Myc; 
Overexpressed in B cell 
non-Hodgkin lymphoma, 





small cell lung cancer, 
oral squamous cell 







PRC1 Ubiquitin ligase E3 
Overexpressed in 
Hodgkin’s lymphoma 
prostate cancer;  
Increase c-Jun and c-Fos; 
Induce anchorage-
independent growth and 
form tumor in nude mice; 
 





Co-operate with c-myc 
and E2Fs; 







osteosarcoma and prostate 
32 
cancer 














Target of E2F1-3; 
Promote anchorage-
independent growth and 
invasion;  
Essential for cell 
proliferation;  
Regulation of actin 
polymerization; 
Prognostic marker of 
aggressive breast cancer 
and prostate cancer; 
Impair DNA repair in 
breast cancer cells;  
Overexpressed in B cell 
non-Hodgkin lymphoma, 
bladder cancer, breast 
cancer, colon cancer, 
gastric cancer; liver 
cancer, lung cancer, 
Hodgkin’s lymphoma, 
mantle cell lymphoma, 
melanoma and prostate 
cancer; 
Esc EED PRC2 Interact with HDACs 
Substrate preference of 
PRC2 
Su(z)12 SUZ12 PRC2 Integrity of PRC2 complex 
Overexpressed in breast 
cancer, colon cancer and 
lung cancer; 
Fusion protein of JAZF1-
SUZ12 in breast cancer. 
Pcl PHF1 PRC2 Interact with EZH2 


































Figure 1.1 Two Distinct Human Polycomb Group Complexes. Each PcG Complex 
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EZH2 IS A MARKER OF AGGRESSIVE BREAST CANCER AND PROMOTES 
NEOPLASTIC TRANSFORMATION OF BREAST EPITHELIAL CELLS 
 
 
Breast cancer is a leading cause of cancer-related death in women, accounting 
for about 40,000 deaths per year in the United States (1). Despite advances in the early 
detection and treatment of breast cancer, mortality for those 20% of patients with 
recurrences and or metastases is about 100% (2). Currently, the most important prognostic 
markers for patients with breast cancer that are used in the clinical setting are components 
of the staging system, such as primary tumor size and the presence of lymph node 
metastasis (3). However, the accuracy of these conventional indicators is not as precise as 
desired, leading to inefficient application of systemic therapy (4). Thus, there is a need for 
novel molecular predictors of tumor behavior at the time of diagnosis that will help guide 
clinical therapy decisions.  
Few biomarkers of breast cancer progression have been proven to be clinically 
useful (4). Estrogen receptor (ER) and progesterone receptor (PR) are highly predictive of 
breast cancer patients that will benefit from endocrine therapy (5) but are weak prognostic 
factors (6). Other tumor markers that have been considered for prognostication in breast 
cancer include erbB2 amplification/overexpression, cathepsin D, and uPAR (4). The 
consensus, however, remains that new prognostic factors that are more precise and 
reliable are needed (7).  
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Through our gene expression profiling studies, we identified EZH2 as being 
overexpressed in metastatic prostate cancer (8). In clinically localized prostate cancer, 
EZH2 was found to be predictive of poor outcome postprostatectomy (i.e., biochemical 
recurrence or metastasis). EZH2 is a Polycomb Group (PcG) protein homologous to 
Drosophila Enhancer of Zeste and involved in gene silencing (9, 10). PcG proteins are 
presumed to function in controlling the transcriptional memory of a cell (9). 
Dysregulation of this gene silencing machinery can lead to cancer (9, 11, 12). In the 
context of prostate cancer, we provided evidence that EZH2 functions as a transcriptional 
repressor, and inhibition of EZH2 blocks prostate cell growth (8). Interestingly, several 
recent studies demonstrated that EZH2 has enzymatic activity and functions as a histone 
H3 methyltransferase (13–15).  
Biochemical analysis indicates that PcG proteins belong to at least two multimeric 
complexes, PRC1 (16) and EED-EZH2 (Enx1) (17). These complexes are thought to 
heritably silence genes by acting at the level of chromatin structure. The EED protein 
interacts directly with type 1 histone deacetylases (HDACs) in mammalian cells (18), and 
in Drosophila (19), and this has been suggested to be part of the silencing mechanism. 
Furthermore, recent studies have demonstrated that EED/EZH2 complexes methylate H3-
K9 and K27 in vitro, with a strong preference for K27 (13–15). Methylation of both H3-
K9 (20) and H3-K27 is thought to be involved in targeting the PRC1 complex to specific 
genetic target loci.  
By interrogating publicly available gene expression data sets, we identified 
EZH2 as being dysregulated in breast cancer. In the present study, we examined EZH2 
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mRNA transcript and protein level in normal breast and in breast cancer progression. 
Immunohistochemical analyses performed on a spectrum of breast cancer specimens 
demonstrated that high EZH2 levels were strongly associated with poor clinical outcome 
in breast cancer patients. EZH2 was an independent predictor of breast cancer recurrence 
and death and provided prognostic information above and beyond known clinical, 
pathologic, and biomarkers studied. Overexpression of EZH2 in normal breast epithelial 
cell lines produced a neoplastic phenotype characterized by anchorage-independent 
growth and cell invasion. Neoplastic transformation mediated by EZH2 depended on both 
the SET domain as well as HDAC activity. Importantly, we propose a biologic basis for 
the association of EZH2 and tumor aggressiveness in that high levels of EZH2 promote 
the invasive potential of carcinomas. 
EZH2 Transcript and Protein Expression Are Elevated in Breast Cancer. 
On the basis of our previous work characterizing EZH2 in prostate cancer (8), we were 
interested in determining whether EZH2 is dysregulated in breast cancer, which, similar 
to prostate cancer, is steroid hormone regulated. This was facilitated by our group's 
ongoing efforts to create a cancer microarray metaanalysis database (see 
www.ONCOMINE.org) stemming from our initial work in prostate (27). Of the five 
publicly available breast cancer gene expression datasets (28–32), only the Perou et al. 
(28) study had neoplastic and normal breast tissues to make comparisons between benign 
and cancer. Interestingly, in this dataset, we found that the EZH2 transcript was 
overexpressed significantly in invasive breast cancer and metastatic breast cancer relative 
to normal (P = 0.002, t test) (28).  
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To validate these DNA microarray results, we carried out SYBR green 
quantitative real-time PCR on 19 laser-capture microdissected normal and invasive breast 
cancers. As predicted, levels of EZH2 mRNA were increased an average of 7.5-fold in 
invasive carcinomas compared with normal breast epithelial cells (t test, P = 0.0085) (Fig. 
2.1A). To confirm that EZH2 is elevated at the protein level in invasive breast cancer, we 
analyzed normal breast and breast cancer tissue extracts by immunoblot analysis. 
Consistent with the transcript data, invasive breast cancer expressed high levels of EZH2 
protein relative to normal (Fig. 2.1B). Importantly, EED, a PcG protein that forms a 
complex with EZH2, did not exhibit similar protein dysregulation.  
Using high-density tissue microarrays, we next evaluated the expression of 
EZH2 protein in a wide range of breast tissues (280 patients, n = 917 samples) to 
characterize its expression in situ by immunohistochemistry. EZH2 protein expression 
was observed primarily in the nucleus (Fig. 2.1C), as reported previously (33). Invasive 
breast cancer that expressed high levels of EZH2 (scores 3–4, EZH2+) and those that 
expressed low levels of EZH2 (scores 1–2, EZH2–) were readily apparent (Fig. 2.1C 
Center and Right). There was a remarkable staining difference between tumor cells that 
form intravascular emboli and adjacent normal breast epithelia (Fig. 2.1C Left). 
Consistent with our mRNA transcript data, EZH2 protein levels were elevated in invasive 
carcinoma relative to normal or atypical hyperplasia (Wilcoxon test, P < 0.0001, Fig. 
2.1D). As in the case of metastatic prostate cancer (8), breast cancer metastases expressed 
high levels of EZH2 (Fig. 2.1D). Median EZH2 staining intensities of normal, atypical 
hyperplasia, ductal carcinoma in situ (DCIS), invasive carcinoma, and metastases were 
1.47 (SE 0.61), 2 (SE 0), 2.38 (SE 0.52), 2.74 (SE 0.99), and 3.09 (SE 1.04), respectively 
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(Fig. 2.1D). Interestingly, increased EZH2 protein and transcript were already present in 
DCIS, a precursor of invasive carcinoma (Fig. 2.1D).  
Prognostic Value of EZH2 in Breast Cancer. To investigate whether EZH2 
mRNA expression levels are associated with outcome, we analyzed the published van't 
Veer et al. (30) breast cancer gene expression dataset, which contains outcome 
information on 78 sporadic invasive carcinomas <5 cm with negative lymph nodes. We 
found that the levels of EZH2 transcript expression were significantly higher in invasive 
carcinomas that metastasized within 5 years of primary diagnosis when compared with 
invasive carcinomas that did not metastasize (Wilcoxon rank test P = 0.01, Fig. 2.2A). By 
Kaplan–Meier analysis, high EZH2 expression [>1.26 (log10 ratio >0.1)] was associated 
significantly with the development of metastasis within 5 years of primary diagnosis (log 
rank P < 0.0001). Multivariable Cox hazards regression analysis showed that EZH2 
mRNA expression was an independent predictor of the development of metastases with a 
hazard ratio of 2.02 (95% confidence interval 1.08–3.76, P = 0.03).  
By using our breast cancer tissue microarray data, we were in the position to 
evaluate clinical and pathology associations of EZH2 protein levels in breast cancer. In 
our cohort of 236 consecutive breast cancer patients (n = 712 samples), 194 had complete 
follow-up information. Clinicopathologic characteristics of the patients can be found in 
Table 2.1. The median age of the study population was 56 years (ranging from 26 to 89 
years). After a median follow-up of 3.2 years (range 17 days to 15.8 years), 42 of the 194 
patients (21.6%) died of breast cancer. The 5- and 10-year disease-specific survival rates 
for the entire cohort of patients were 60.28% and 38.66%, respectively. The association 
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between EZH2 protein levels and clinical characteristics is shown in Table 2.3, which is 
published as supporting information on the PNAS web site. EZH2 expression was 
strongly associated with standard pathology predictors of clinical outcome, including 
tumor diameter (P = 0.002) and stage of disease (P < 0.0001). Higher EZH2 levels were 
also significantly associated with decreasing age (P = 0.0003), negative ER status (P = 
0.0001), negative PR status (P < 0.0001), and lymph node status (P = 0.001), but not 
HER2/neu overexpression. Hazard ratios of recurrence or metastasis according to EZH2 
status were 2.92 (P < 0.0001).  
The results of the univariate analysis are shown in Table 2.4, which is published 
as supporting information on the PNAS web site. As expected, at the univariate level, 
lymph node status, tumor diameter, and stage of disease were associated with disease-
specific and overall survival. Hormone receptor status was inversely associated with 
outcome. We found a strong association between EZH2 protein levels and patient 
outcome. Higher EZH2 protein levels were associated with a shorter disease-free interval 
after initial surgical treatment, lower overall survival, and a high probability of disease-
specific death (or death due to breast cancer) (Fig. 2.2 B and C). The 10-year disease-
free survival for patients with tumors expressing high EZH2 levels was 24.76% and, by 
contrast, 58.92% for low levels of EZH2 (log rank P < 0.0001, Fig. 2.2B). High EZH2 
expression was associated with disease-specific survival in patients with lymph node-
negative disease (log rank P = 0.007). EZH2 expression was associated with disease-
specific survival in patients with stage I and II disease (log rank, P = 0.037 and P = 0.048, 
respectively), but not in patients with advanced stage (stages III and IV). EZH2 was not 
associated with survival in patients with positive lymph nodes. The strong inverse 
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association between high EZH2 protein expression and negative ER status (Kruskal–
Wallis test, P = 0.001, Table 2.3) prompted us to investigate whether the prognostic 
utility of EZH2 depends on ER status. Kaplan–Meier analysis showed that EZH2 levels 
were strongly associated with outcome in both ER-positive and -negative invasive 
carcinomas. Thus, our data suggest that EZH2 has prognostic utility independently of ER 
status.  
The best multivariable model predictive of disease-specific survival included 
positive lymph nodes, high EZH2 expression, and negative PR status (Table 2.2). High 
EZH2 expression was a strong independent predictor of outcome providing survival 
information above other independent prognostic features, with a hazard ratio of 2.04 and a 
95% confidence interval of 1.17–3.57, P = 0.01. Tumor size, angiolymphatic invasion, 
and ER status, identified as having strong associations with EZH2 at the univariate level, 
were not independently associated with outcome at the multivariable level.  
EZH2 Overexpression Promotes Anchorage-Independent Growth and 
HDAC Activity in Normal Breast Epithelial Cells. To study the function of 
dysregulated EZH2 expression in breast epithelial cells, we generated adenovirus 
constructs expressing EZH2. We also generated an adenovirus expressing a mutant 
version of EZH2 in which the C-terminal SET domain is truncated (EZH2∆SET). Normal 
immortalized breast epithelial cells (H16N2) (34) were infected with EZH2 and 
EZH2∆SET expressing viruses and protein expression demonstrated in Fig. 2.3A. 
Overexpression of EZH2 in breast epithelial cells did not significantly enhance cell 
proliferation in tissue culture (Fig. 2.3B). Interestingly, EZH2 overexpression markedly 
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promoted colony formation in soft agar relative to EZH2∆SET and vector controls (Fig. 
2.3 C and D). In fact, colonies were present only in EZH2-infected H16N2 cells, 
supporting the notion that EZH2 can facilitate anchorage-independent growth. As in our 
previous study with prostate cells (8), overexpression of EZH2 in breast carcinoma cells 
induced transcriptional repression of a cohort of target genes (data not shown). Previous 
studies have demonstrated that the EED–EZH2 complex recruits type I HDACs (18). To 
determine whether overexpression of EZH2 modulates HDACs, we measured HDAC 
enzymatic activity in breast epithelial cell lysates. Overexpression of EZH2 but not the 
EZH2∆SET mutant increased total HDAC activity in breast epithelial cells. This activity 
was completely abrogated in the presence the HDAC inhibitor TSA.  
Dysregulated EZH2 Orchestrates the Invasive Potential of Breast Epithelial 
Cells. We next assessed the biological function of EZH2 in the context of cancer cell 
invasion. We observed that overexpression of EZH2 in breast epithelial cells promotes 
invasion in a reconstituted basement membrane invasion chamber assay (Fig. 2.4 A and 
B). The control experiments that included EZH2 SET mutant and vector did not exhibit 
similar proinvasive properties. Importantly, EZH2-mediated invasion was attenuated with 
inclusion of the HDAC inhibitors TSA and SAHA. Cell invasion was quantitated by both 
cell counting and colorimetry (Fig. 2.4B). Next, we used SU-ECM (25, 35) as invasion 
substrates to examine the invasive properties of EZH2 expressing breast epithelial cells. 
The SU-ECM assay has advantages over the reconstituted basement membrane assay in 
that it is a uniform, biological, serum-free basement membrane that closely mimics the 
type of extracellular matrix that cells encounter in vivo. As with the reconstituted 
basement membrane assay, EZH2 overexpression in the SU-ECM assay supported similar 
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findings regarding the invasive potential of EZH2 and its requirement for HDAC activity 
(Fig. 2.4C).  
To examine the role of EZH2-mediated invasion in an in vivo setting, we used a 
CAM assay. In this model, EZH2 overexpressing breast epithelial cells are labeled with 
fluorescent beads, seeded in duplicate on CAMs, of 10-day-old chicken embryos and 
incubated. At time of harvest, frozen sections were made from the CAM tissues and 
examined by fluorescent and light microscopy after hematoxylin/eosin staining. EZH2 
overexpressing breast epithelial cells consistently promoted invasion of the CAM (a 
representative experiment is shown in Fig. 2.4D). 
In the present study, we characterized the expression pattern of EZH2 transcript 
and protein in a wide spectrum of breast disease and assessed the utility of EZH2 as a 
prognostic marker in patients with breast cancer. EZH2 is significantly increased in 
invasive carcinoma and breast cancer metastases at both the transcript and protein levels 
when compared with normal breast tissues. Cells forming intravascular tumor emboli had 
strikingly increased EZH2 expression (Fig. 2.1C Left), suggesting that EZH2 may play a 
role in vascular invasion and breast cancer metastasis. In vitro and in vivo experiments in 
which EZH2 was ectopically overexpressed in normal mammary epithelial cell lines 
provide biological evidence that EZH2 can mediate anchorage-independent growth and 
cell membrane invasion, hallmarks of cancer (36). This is especially intriguing in that 
EZH2, which targets transcriptional repression of target genes, presumably mediates an 
invasive cancer phenotype.  
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To test the clinical utility of EZH2 protein expression as a prognostic biomarker 
of breast cancer progression, we evaluated the associations between EZH2 and survival 
after treatment. At the univariate level, EZH2, tumor stage, tumor size, the presence of 
axillary lymph node metastases, and hormone receptor status were all significantly 
associated with survival. In a multivariable Cox regression analysis, high EZH2 
expression and lymph node metastasis were independent predictors of outcome. The 
single best multivariable model included high EZH2 levels, positive lymph nodes, and 
negative PR status. In silico analysis of the cDNA expression profiling of breast cancer 
performed by van't Veer et al. (30) showed that high EZH2 levels were associated with 
the development of metastasis within 5 years of primary diagnosis in patients with 
sporadic invasive carcinomas. These findings support the potential clinical utility of 
incorporating EZH2 into clinical nomograms to help determine the risk of cancer 
progression.  
A major limitation of our analysis is its retrospective nature, which precludes an 
accurate analysis of survival in the context of hormonal or adjuvant treatment. In our 
patient cohort, 88% ER-positive tumors received hormonal treatment. Thus, we critically 
evaluated the prognostic significance of EZH2, taking into account tumor ER status. 
EZH2 was strongly associated with clinical outcome in hormone-dependent and -
independent breast cancer patients, indicating that the prognostic power of EZH2 is 
independent of ER status. Future studies will test the model developed in this study on a 
validation cohort to confirm these initial observations.  
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The prognostic significance of EZH2 as biomarker for aggressive breast cancer 
is likely linked to its biological functions. EZH2 is a member of a group of polycomb 
proteins that are involved in maintaining heritable gene expression profiles and thus 
regulate cell type identity. Thus, dysregulation of the transcriptional machinery of a cell 
may result in loss of cell type identity and neoplastic transformation. Here we provide 
biological evidence that dysregulated EZH2 promotes oncogenic transformation. 
Overexpression of EZH2 in breast epithelial cells induced anchorage-independent growth 
and cell invasion. Invasive properties of EZH2 overexpressing cells were demonstrated in 
both in vitro assays (i.e., basement membrane invasion chamber and SU-ECM assays) as 
well as in an in vivo assay (i.e., CAM). EZH2 overexpression induced HDAC enzymatic 
activity in breast epithelial cells. Interestingly, EZH2-mediated cell invasion are 
abrogated by the HDAC inhibitors TSA and SAHA, implying that EZH2-mediated 
invasion requires HDAC activity. Previous reports have shown that type I HDACs are 
recruited to the EZH2-EED PcG complex (18). Our group and other groups have found 
that EZH2-mediated gene silencing requires an intact SET domain and recruitment of 
HDAC activity (8), and that inhibition of HDAC activity blocked the transcriptional 
repressor functions of EZH2. Several HDAC inhibitors, including SAHA, have been 
shown to have promise clinically as antitumorigenic agents (37). Thus, we suggest that 
inhibitors of HDAC may be useful therapeutic compounds in EZH2 overexpressing 
tumors. In addition, the HDAC activity induced by EZH2 may explain the intriguing 
strong association between EZH2 protein expression and negative ER, and one might 
speculate that EZH2 may transcriptionally repress ER. Further investigation in this area 
may be warranted.  
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Several recent studies provide strong evidence that EZH2 has inherent activity 
as a histone H3 methyltransferase, which may represent the mechanism of PcG silencing 
(10, 13–15). Cao et al. (13) present evidence that the specific target of EZH2 is lysine 27 
on the histone H3 N-terminal tail (13). If EZH2 plays a role in breast cancer progression, 
its inherent methyltransferase activity may serve as an attractive therapeutic target. 
Together, these studies suggest that the transcriptional memory machinery of a cell may 
have a role in cancer progression.  
In summary, we discovered that EZH2 is a promising biomarker of aggressive 
breast cancer, not only extending our initial observations in prostate cancer but also 
suggesting that EZH2 (and thus the cell memory machinery) may have a role in 
carcinoma progression in malignancies from hormonally regulated tissues. Clinically, our 
retrospective studies suggest that EZH2 levels can be used to identify patients with breast 
cancer of a more aggressive phenotype, thereby enhancing our prognostic knowledge. 
Although our results are promising, EZH2 expression needs to be validated in 
relationship to outcome in the context of carefully controlled clinical trials. If confirmed, 
application of EZH2 immunohistochemical analysis should be technically straightforward 
and feasible. In addition to the potential prognostic utility of EZH2, we also provide a 
biologic mechanism for its association with aggressive cancers, by mediating anchorage-
independent growth and cell invasion.  
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Materials and Methods 
Selection of Patients and Tissue Microarray Development. Breast tissues for 
tissue microarray construction were obtained from the Surgical Pathology files at the 
University of Michigan with Institutional Review Board approval. A total of 280 cases (n 
= 917 tissue microarray samples) were reviewed by the study pathologist and arrayed in 
three high-density tissue microarrays, as described (21, 22). At least three tissue cores 
(0.6-mm diameter) were sampled from each block to account for tissue and tumor 
heterogeneity. The TMAs contained the whole spectrum of breast pathology, with 
samples of normal breast, atypical hyperplasia, ductal carcinoma in situ, invasive 
carcinoma, and breast cancer metastases. The invasive carcinomas were obtained from 
194 consecutive patients (n = 621 tissue microarray elements) with follow-up information 
at the University of Michigan between 1987 and 1991. Clinical and treatment information 
was extracted by chart review, performed by the surgeon on the study (M.S.S.), with IRB 
approval. Of the 385 cases of invasive carcinoma of the breast treated at our institution 
from 1987 to 1991, 236 were available for study. The reasons for exclusion of cases were: 
(i) unavailability of tissue slides or blocks, and (ii) primary resection performed at a 
referring institution. In our cohort of 236 consecutive breast cancer patients (n = 712 
specimens), 194 had complete follow-up information. The median duration of follow-up 
was 3.2 years (range 17 days to 15.8 years). Clinical and pathological variables were 
determined following well-established criteria. The histological grade was assessed 
according to the method described by Elston and Ellis (3); angiolymphatic invasion was 
classified as either present or absent.  
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Immunohistochemical Studies. Immunohistochemistry was performed on the 
tissue microarrays (TMAs) by using standard biotin–avidin complex technique and a 
polyclonal antibody against EZH2 that was previously validated by immunoblot analysis 
(8). EZH2 expression was evaluated at least three times for every tissue microarray 
element and at least nine times for each tumor by using a previously validated Web-based 
tool (TMA Profiler, University of Michigan, Ann Arbor, MI). Using this method, the 
pathologist is blinded to tumor stage and clinical information. The highest value of all 
measurements from a single individual was used for subsequent analysis. Nuclear EZH2 
expression was scored by using a validated system as negative (score = 1, no staining); 
weak (score = 2, < 25% of nuclei staining, any intensity); moderate (score = 3, 25--75% 
of nuclei staining, any intensity); and strong (score = 4, >75% of nuclei staining, any 
intensity). High EZH2 was defined as scores 3 and 4; low EZH2 was defined as scores 1 
and 2. The TMAs were immunostained for ER and PR and for HER-2/neu by using well 
described and validated procedures (23). For estrogen receptor (ER) staining, we used ER 
antibody clone 6F11 (Ventana Medical Systems, Tucson, AZ), prediluted with antigen 
retrieval by using a microwave in 10 mM citrate buffer. For progesterone receptor (PR), 
we used antibody clone 636 (DAKO) at 1:400 dilution, subjected to 95˚C water bath for 
40 min; and for HER2/neu immunostaining, we used CB11 antibody (NovoCastra, 
Burlingame, CA) at 1:40 dilution, with microwave antigen retrieval with 10 mM citrate 
buffer. Hormone receptor status was reported as positive or negative when >10% of the 
neoplastic cells exhibited nuclear staining. HER-2/neu status was reported as 0-3+. As 
previously reported, we found almost perfect correlation between the hormonal status, as 
determined in the TMAs and in standard whole-tissue sections. 
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Statistical Analysis. Comparison of the intensity of EZH2 staining between 
normal breast, hyperplasia, ductal carcinoma in situ, invasive carcinoma, and metastases 
was carried out by calculating the median staining intensity for each case and applying 
the Wilcoxon rank test. A P value of <0.05 was considered significant. Overall survival 
was calculated from the date of surgical excision of the primary tumor to the date of death. 
Patients who died of or with the disease were included in the analysis. For disease-
specific survival, data for patients who died from other causes were censored at the time 
of death. Overall survival and disease-specific survival curves were constructed by the 
Kaplan–Meier method. Clinical criteria for treatment failure were local recurrence and/or 
the development of metastases.  
Univariate analyses of disease-specific survival were performed by using a two-
sided log-rank test to evaluate EZH2 protein expression, age, tumor size, nodal status, 
stage, angiolymphatic invasion, ER status, PR status, and HER-2/neu status. To assess the 
influence of several variables simultaneously, a multivariable Cox proportional hazards 
model of statistically significant covariates was developed by removing nonsignificant 
parameters in a step-wise manner. Statistical significance in the Cox models was 
determined by Wald's test.  
SYBR Green Quantitative Real-Time PCR. We performed SYBR green real-
time quantitative PCR analysis on 19 laser-microdissected frozen breast tissues obtained 
from the frozen breast tissue bank in our institution with IRB approval. Briefly, 4-µm-
thick frozen sections of six normal breast tissues, obtained from patients that underwent 
reduction mammoplasties and 13 patients with invasive carcinomas, were cut and stained 
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with hematoxylin/eosin (H&E) and subsequently subjected to laser capture 
microdissection (µCut, SL-Microtest, Glattsbrugg, Switzerland). Total RNA was isolated 
from each sample by using the Absolutely RNA Microprep Kit (Stratagene), according to 
the manufacturer’s instructions. Each sample was then vacuum concentrated and reverse 
transcribed into first-strand cDNA by using Superscript II Reverse Transcriptase 
(Invitrogen) in the presence of GeneFilter Primer PolydT and random hexamer primers 
(Invitrogen) and resuspended in 20 m l of DNAse/RNAse free water (GIBCO/BRL). For 
each QRT-PCR amplification, 4 m l of the cDNA product, 12.5 m l of 2´ SYBR green 
PCR Master Mix (Applied Biosystems), 1 m l containing 25 ng of both the forward and 
reverse EZH2 primers [or 50 ng of both the forward and reverse hydroxymethylbilane 
synthase (HMBS) primers], and 7.5 m l of DNAse/RNAse free water was added for a 
final volume of 25 m l. Thermocylcling conditions were as suggested by the 
manufacturer: 95° for 10 min to activate the polymerase followed by 40 cycles of 95° for 
15 sec and 60° for 1 min. To confirm the absence of nonspecific amplification and primer 
dimer binding, a no-template control well was included, and amplified products were 
separated on a 1.5% agarose gel to confirm the expected product size. Threshold levels 
were set by using SDS Ver. 1.7 software (Applied Biosystems), and the quantity of DNA 
in each sample was calculated by interpolating its Ct value from a standard curve of Ct 
values obtained from serially diluted breast cancer cDNA with Microsoft EXCEL. All 
standard curves had R2 values ≥0.99 over three orders of magnitude. The calculated 
quantity of EZH2 from each sample was then divided by the average calculated quantity 
of the housekeeping gene HMBS corresponding to each sample to give a relative 
expression of EZH2 for each sample. QRT-PCR was performed in duplicate for EZH2 
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and HMBS expression in each sample, and mean EZH2/HMBS is reported. The EZH2 
oligonucleotide primers were designed by using Primer Select (DNASTAR, Madison, WI) 
to minimize primer--dimer formation and amplify cDNA products spanning an intron--
exon junction to eliminate amplification of genomic DNA. The oligonucleotide 
sequences are as follows: EZH2-F (5’ -3’) GCG CGG GAC GAA GAA TAA TCA T, 
EZH2-R (5’ -3’ ) TAC ACG CTT CCG CCA ACA AAC T. 
Immunoblot Analysis. Protein extracts were prepared from normal and 
cancerous breast tissues by using NP-40 lysis buffer containing 50 mM Tris, pH 7.4; 1% 
Nonidet P-40; and a cocktail of protease inhibitors. Fifteen micrograms of proteins was 
boiled in sample buffer, separated by SDS/PAGE, and transferred onto nitrocellulose 
membrane. The membrane was incubated for 1 hr in blocking buffer [Tris-buffered saline 
with 0.1% Tween (TBS-T) and 5% nonfat dry milk] and incubated overnight at 4°C with 
anti-EZH2 rabbit polyclonal antibody at a dilution of 1:1,000 in blocking buffer. After 
washing in TBS-T, the blot was incubated with horseradish peroxidase-conjugated 
secondary antibody, and the signals were visualized by the enhanced chemiluminescence 
system as described by the manufacturer (Amersham Pharmacia). The blot was reprobed 
with β-tubulin to confirm equal loading of the different tissue samples 
Adenovirus Constructs. Adenoviral constructs were generated by in vitro 
recombination. In brief, the full-length EZH2 or SET domain deleted EZH2 (EZH2 SET) 
were inserted in an adenoviral shuttle plasmid [pACCMVpLpA(–)loxP-SSP]. Viruses 
were generated by transfection into the 293-complementation cell line. Virus was 
propagated in 911 cells and purified on a CsCl gradient. Multiplicities of infection were 
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calculated, and purified viruses were stored in 10 mM Tris·HCl (pH 7.4)/137 mM NaCl/5 
mM KCl/1 mM MgCl2 in 10% glycerol (by volume).  
Cell Count. H16N2 were infected with EZH2 adenovirus. Cell counts were 
estimated by trypsinizing cells and analysis by Coulter counter at the indicated time 
points in triplicate.  
Soft Agar Assay. A 0.6% (wt/vol) bottom layer of low melting point agarose in 
normal medium was prepared in six-well culture plates. On top, a layer of 0.6% agarose 
containing 1 x 105 stable transfected cells was placed (24). After 25 days, foci were 
stained with P-Iodonitrotetrazolium violet and counted.  
HDAC Assay. HDAC activity assays were performed according to the 
manufacturer instructions (Biomol, Plymouth Meeting, PA). Briefly, cell lysates were 
prepared by using lysis buffer (Biomol) from the H16N2 cells that were infected with 
EZH2, EZH2 SET, and vector virus, and substrate was added and incubated for 30 min 　
at room temperature. For HDAC inhibitor treatment, TSA were added to the lysate and 
incubated at room temperature for 30 min. The reaction was stopped, and fluorescence 
was measured at excitation range of 340-380 nm and emission range of 440-460 nm 
(Packard Fluorocount). 
Basement Membrane Matrix Invasion Assay. Cells were infected with vector, 
EZH2, and EZH2∆SET adenovirus. Forty-eight hours after infection, the cells were 
trypsinized and seeded at equal numbers onto the basement membrane matrix 24-well 
culture plates [extracellular membrane (ECM); Chemicon] in the presence or absence of 
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HDAC inhibitors suberoylanilide hydroxamic acid (SAHA) (7.5 µM) and trichostatin A 
(TSA) (0.5 µM). FBS was added to the lower chamber to act as a chemoattractant. After 
48-h incubation, the noninvading cells and ECM were removed gently by cotton swab. 
The cells that are invaded that are present on the lower side of the chamber were stained, 
air dried, and photographed. The invaded cells were counted under the microscope. For 
colorimetric assay, the inserts were treated with 150 µl of 10% acetic acid, and 
absorbance was measured at 560 nm.  
Sea Urchin (SU) Embryo Basement Membrane Invasion Assay. H16N2 
cells were infected with vector, EZH2, and EZH2  SET adenovirus and trypsinized after 　
48 hr. The infected cells alone or treated with HDAC inhibitors SAHA (7.5 µM) and 
TSA (0.5 µM) and analyzed for invasiveness by using the SU embryo basement 
membrane invasion assay (25). The trypsinized cells were then resuspended to a 
concentration of 20,000 cells/ml in the appropriate media. The cells were layered on top 
of the embryo basement membrane invasion substrates and incubated for 4 hr at 37°C. 
Relative invasion was scored by phase-contrast microscopic examination. For each 
sample, 50-100 SU extracellular matrix (ECM) were examined, and the ratio of cells 
located inside vs. adhering to the outside of the SU-ECMs was calculated.  
Chick Chorioallantoic Membrane (CAM) Invasion Assay. EZH2 and control 
virus-infected H16N2 cells were labeled with Fluoresbrite carboxylated polystyrene 
nanospheres (26) of 48 nm diameter (Polysciences) as described forty-eight hours after 
infection. The cells were detached from the culture dish with 2 mM EDTA in PBS, 
counted, and resuspended in 50 µl of PBS with Ca2+ and Mg2+. To apply cells onto the 
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CAM of 10-day chick embryos, in which an artificial air sac was created, a 1-cm-
diameter-wide window was opened aseptically in the flat pole of the eggshell with an 
electric drill (Dremel moto-tool, Emerson, Racine, WI). The resuspended labeled cells 
(106 cells/CAM) were then applied onto the small patch of the CAM. The embryo was 
returned to the incubator in an upright position after inoculation and remained there for 
additional 48 hr. At time of harvest, frozen sections were made from the CAM tissues 
after immersion in 10% formaldehyde. The frozen sections were mounted with 
Vectashield mounting media with 4',6-diamidino-2-phenylindole (Vector Laboratories), 
monitored under a fluorescent microscope (Leica DMLB, Leica, Wetzlar, Germany) and 
photographed with the SPOT cooled color digital camera (Diagnostic Instruments, 
Sterling Heights, MI). The serial sections were also prepared and stained with H&E as 
histological sections. 
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Table 2.1 Demographics of patients with clinical follow-up used in this study 
 
Parameter value 
No. of patients 194 
Median age, years (range) 56 (26-89) 
Follow-up/years, median (range) 3.2 years (17 d-16 years) 
Pathologic stage, no. (%)  
I 78 (40) 
II 66 (34) 
III 32 (16) 
IV 18 (10) 
Tumor size, cm (range) 2 (0.3-6.7) 
Lymph node status, no. (%) 67 (36) 
Negative 78 (44) 
Positive  
ER status, no. (%)  
Negative 67 (36) 
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Positive 120 (64) 
PR status, no. (%)  
Negative 86 (45) 
Positive 107 (55) 
HER-2/neu status, no. (%)  
Negative 163 (85) 






Table 2.2 Independent factors predictive of death from breast cancer 
 
Parameter p value Hazard ratio 
95% confidence 
interval for hazard 
ratio 
EZH2 positive 0.01 2.04 1.17 3.57 
Positive lymph 
nodes (≥4, 1-3, 0) 
<0.0001 1.9 1.4 2.57 
PR positive (vs. 
negative) 
0.02 0.54 0.32 0.91 
 







Table 2.3 Association between EZH2 and clinical characteristics 
Variable N Wilcoxon P value 
Age (£ 50, >50) 194 0.0003 
Positive lymph node (0, 1-3, ³ 4) 177 0.001 
Size (£ 2, >2) 182 0.002 
TNM Stage (1, 2, 3, 4) 176 <0.0001 
ER status (positive, negative) 187 0.0001 
PR status (positive, negative) 193 <0.0001 
HER2NEU (positive, negative) 191 0.8 
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Variable N P value Hazard ratio 95% confidence interval 
for hazard ratio 
EZH2 194 <0.0001 2.65 1.64 4.29 
Lymph node status 177 <0.0001 1.97 1.51 2.59 
Age 194 0.05 0.64 0.42 0.99 
Tumor size 182 0.004 1.94 1.23 3.06 
Stage 176 <0.0001 2.37 1.72 3.25 
ER 187 0.002 0.50 0.32 0.78 
PR 193 0.0006 0.47 0.30 0.72 












Fig. 2.1 EZH2 mRNA transcript and protein levels are elevated in breast cancer. (A) 
Quantitative SYBR green RT-PCR of EZH2 transcript in laser-capture microdissected 
normal and breast cancer epithelia. Each sample was performed in duplicate, and a ratio 
was calculated relative to the housekeeping gene hydroxymethylbilane synthase (HMBS). 
(B) Immunoblot analysis of EZH2 and EED in breast tissue extracts. Metastatic (Met) 
prostate cancer was used as a positive control. β-Tubulin was included as a loading 
control. (C) Representative breast tissue sections stained with an antibody to EZH2. (Left) 
Normal breast epithelia (open triangle) and adjacent intravascular breast cancer emboli 
(filled triangle). (Center) An invasive breast cancer expressing high levels of EZH2. 
(Right) An invasive breast cancer expressing low levels of EZH2. (D) Tissue microarray 
analysis of EZH2 expression in breast cancer progression. Tumor specimens were 
stratified into high EZH2 expressors (filled bars, scored 3 or 4) and low EZH2 expressors 


















Fig. 2.2 High EZH2 levels are associated with aggressive breast cancer. (A) Kaplan–
Meier analysis of metastasis-free survival according to EZH2 mRNA transcript levels as 
measured using DNA microarrays by van't Veer et al. (30). Kaplan–Meier analysis of 
disease-specific (B) and overall (C) survival according to EZH2 protein levels as 
assessed by immunohistochemical analysis. Patients grouped on the basis of high (+) or 
































Fig. 2.3. Anchorage-independent growth mediated by EZH2. (A) Immunoblot 
analysis of breast cell line H16N2 infected with adenovirus encoding EZH2 or 
EZH2∆SET mutant. (B) Ectopic overexpression of EZH2 does not significantly enhance 
growth of breast epithelial cells in culture. H16N2 cells were infected with EZH2 
adenovirus and controls, and cells were counted at indicated time points. LacZ 
adenovirus and vector adenovirus were used as controls. (C) EZH2 expression enhances 
anchorage-independent growth in vitro. H16N2 cells were infected with EZH2, 
EZH2∆SET, or vector adenoviruses. Anchorage-independent growth was determined by 
assaying colony formation in soft agar. After 25 days, the plates were stained and 
photographed. (D) Quantitation of soft agar colonies from experiments described in C. 
Colonies from three wells were quantitated for each condition. (E) EZH2 induces HDAC 
activity in breast epithelial cells. HDAC activity was measured in extracts from H16N2 
cells infected with indicated viruses ± treatment with TSA (1.0 µM). As indicated by the 
manufacturer (Biomol), nuclear extracts from HeLa cells were used as positive controls. 


































Fig. 2.4. EZH2 orchestrates cell invasion both in vitro and in vivo. (A) A reconstituted 
basement membrane invasion chamber assay (Chemicon) was used to assess breast 
epithelial cell lines infected with EZH2 and control adenoviruses. Representative fields of 
invaded and stained cells are shown. (B) The numbers of invaded cells were counted in 
six fields, and the mean values were determined. Quantitation by colorimetry (absorbance 
at 560 nm) is shown in Inset. (C) EZH2-mediated invasion of SU-ECM. H16N2 cells 
were infected with EZH2, EZH2∆SET, or control adenoviruses. (D) EZH2 
overexpression mediates invasion of breast epithelial cells in a CAM assay. (Upper) 
CAM tissues stained with hematoxylin/eosin. Arrows indicate the cells that have invaded 
the CAM. Because cells were labeled with Fluoresbrite carboxylated polystyrene 
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REPRESSION OF E-CADHERIN BY THE POLYCOMB GROUP PROTEIN 
EZH2 IN CANCER 
 
 
Tumor invasion and metastasis are the major catalysts of morbidity and mortality 
in cancer patients (1, 2). The initial stages of tumor invasion are characterized by the 
disruption of cell-cell adhesion, and decreased E-cadherin expression characterizes the 
invasive phenotype.   E-cadherin is a Ca2+-dependent, transmembrane receptor that 
mediates cell-cell adhesion at adherent junctions via homophilic binding, thus 
maintaining epithelial cellular adhesion and integrity. (3).  There is compelling evidence  
that E-cadherin expression is repressed in cancer, which suggests that it may play a 
critical role in the malignant progression of epithelial tumors (4-6). It has been implicated 
as a tumor suppressor via negative regulation during the course of  invasion (7, 8). While 
many epithelial cancer cell lines that lack E-cadherin  expression were invasive, 
administrative of  exogenous E-cadherin to these cells prevented invasion, suggesting a 
critical role for this receptor  in invasive process (7) .  E-cadherin  forms dimers, and the 
cytoplasmic domain of E-cadherin  is complexed with catenins that are linked to the actin 
cytoskeleton network of the cells (9). The interaction between these molecules regulate 
the cell-cell adhesion(10).   
Reduced E-cadherin expression has been linked to metastasis. Numerous studies 
have demonstrated that aberrant expression of E-cadherin is associated with the 
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development of metastases in breast cancer (11, 12) and gastric cancer (13) among others. 
A number of mechanisms have been suggested for the repression of E-cadherin function 
during cancer progression including promoter methylation, mutations, transcriptional 
repression by snail and slug, ubiquitination and degradation of the E-cadherin, and 
lysosomal targeting of the E-cadherin for degradation (14-20) . 
 Recent studies have shown that histone H3 lysine 27 trimethylation, which is 
mediated by EZH2 at the promoters of the gene, leads to silencing of gene expression 
(21-23).  As part of a multi-protein complex with the other members of PRC2 (24),  
EZH2 trimethylates histone H3 tails at lysine 27 (25, 26). This epigenetic modification is 
also known to be responsible for X-inactivation (27).  Previously, we demonstrated that 
EZH2 is upregulated in aggressive prostate and breast tumors (28, 29).  Several reports 
have also shown that EZH2 is over-expressed in other aggressive tumors including 
bronchial cancer (30) melanoma (31), bladder cancer (32) liver cancer (33), as well as in 
vitro cancer cell lines such as SKBR3, MDA-MB-231, T47D breast cell lines (34), and  
the prostate cell lines DU145 and LNCaP (35)  .    
EZH2 is a transcriptional repressor that plays a crucial role in maintaining the 
delicate homeostatic balance between gene expression and repression, the disruption of 
which may lead to oncogenesis (36-38).  Recent studies revealed  that EZH2 can 
physically recruit DNA methyltransferases (DNMTs) to certain target genes and silence 
them, suggesting cross-talk between the two distinct epigenetic silencing mechanisms (39, 
40). Cancer cells that contain DNA-methylated genes are specifically packaged in 
nuclesomes with the histone H3K27 trimethylation (41). Reports also suggest that stem 
cell polycomb group targets are more likely to exhibit cancer-specific promoter DNA 
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hypermethylation and histone H3 trimethylation of Lys27 relative to non-targets (42, 43). 
In human and mouse embryonic stem cells, as well as in Drosophila,  Polycomb Group 
(PcG) proteins contribute to pluripotency and plasticity via repression of developmental 
transcriptional factors that normally promote differentiation (44-47).  
In this study, we explored the role of histone methylation mediated by PRC2 in 
the silencing of E-cadherin during cancer progression and provide evidence of a 
functional link between dysregulation of EZH2 and repression of E-cadherin during 
cancer development. 
Materials and Methods   
Basement Membrane Matrix Invasion Assay 
For invasion assays, the breast cell lines H16N2, HME, and MCF10A (ATCC, 
Manassas, VA), as well as normal prostate epithelial cells (PrEC, Cambrex, East 
Rutherford, NJ), were infected with vector, EZH2 and EZH2∆SET adenovirus. Forty-
eight hours post-infection, cells were seeded onto the basement membrane matrix (EC 
matrix, Chemicon, Temecula, CA) present in the insert of a 24 well culture plate. Fetal 
bovine serum was added to the lower chamber as a chemoattractant with or without 
HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) (Biovision Inc., Mountain 
View, CA). After 48 hours, the non-invading cells and EC matrix were gently removed 
with a cotton swab. Invasive cells located on the lower side of the chamber were stained 
with crystal violet, air dried and photographed. They were then enumerated 
microscopically using multiple representative areas. For colorimetric assays, the inserts 
were treated with 150 µl of 10% acetic acid and the absorbance measured at 560nm using 





The knockdown of EZH2 was accomplished with either siRNA duplex 
(Dharmacon, Lafayette, CO) as previously described (28) or shRNA expression vectors 
(Open Biosystems, Huntsville, AL). E-cadherin knockdown was performed using siRNA 
duplex. (Dharmacon) 
Immunoblot Analyses 
The breast cell lines H16N2, HME, and MCF10A, as well as normal prostate 
epithelial cells, were grown to 60% confluency and infected with either EZH2 adenovirus, 
vector control, or Delta SET virus for 48 hours. Cells were homogenized in NP40 lysis 
buffer (50 mM Tris-HCl, 1% NP40, pH 7.4, Sigma, St. Louis, MO), and complete 
proteinase inhibitor mixture (Roche, Indianapolis, IN). Ten micrograms of each protein 
extract were boiled in sample buffer, separated by SDS-PAGE, and transferred onto 
Polyvinylidene Difluoride membrane (GE Healthcare). The membrane was incubated for 
one hour in blocking buffer [Tris-buffered saline, 0.1% Tween (TBS-T), 5% nonfat dry 
milk] and incubated overnight at  4ºC with the following:  anti-EZH2 mouse monoclonal 
(1:1000, 1:5000 in dilution buffer, BD Biosciences, San Jose, CA), anti-E-CAD mouse 
monoclonal antibodies (1:1000, 1:5000 in dilution buffer, BD Biosciences),  anti-EED 
rabbit polyclonal antibody ( 1:1000 in dilution buffer, Upstate, Charlottesville, VA), and 
anti-SUZ12 rabbit polyclonal antibodies (1:1000 in dilution buffer, kind gift from Prof. 
Otte).  Following a wash with TBS-T, the blot was incubated with horseradish 
peroxidase-conjugated secondary antibody and the signals visualized by enhanced 
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chemiluminescence system as described by the manufacturer (GE Healthcare). The blot 
was re-probed with β-tubulin for confirmation of equal loading. 
Northern blot analyses 
Total RNA was isolated from H16N2 cells that were infected with either vector, 
EZH2, or EZH2∆SET adenovirus.  An additional set of cells were infected with EZH2 
adenovirus and were treated with HDAC inhibitor SAHA (Biovision, Mountain View, 
CA).   Twenty micrograms of total RNA from each condition were resolved on a 
denaturing-formaldehyde agarose gel and subsequently transferred onto a Hybond-NX 
membrane (Amersham Biosciences, Piscataway, NJ). EZH2, E-cadherin, and GAPDH 
probes were labeled with p32dCTP (GE Healthcare) and hybridized to the blots.  The 
signal was visualized and quantified using a Typhoon Scanner 9000B and Image Quant 
Software (Amersham Biosciences). E-cadherin and EZH2 signals were normalized to 
that of GAPDH.   
SYBR Green Quantitative Real-Time PCR 
Total RNA was isolated from H16N2 cells that were infected either with vector, 
EZH2, or EZH2∆SET adenovirus. Quantitative PCR (QPCR) was performed using 
SYBR Green dye on an Applied Biosystems 7300 Real Time PCR system (Applied 
Biosystems, Foster City, CA).  Briefly, 1 µg of total RNA was reverse transcribed into 
cDNA using SuperScript III (Invitrogen, Carlsbad, CA) in the presence of random 
hexamers and oligo dT primers (Invitrogen).  All reactions were performed in duplicate 
with SYBR Green Master Mix (Applied Biosystems) plus 25 ng of both the forward and 
reverse primer according to the manufacturer’s recommended thermocycling conditions,  
then subjected to melt curve analysis. Threshold levels for each experiment were set 
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during the exponential phase of the QPCR reaction using Sequence Detection Software 
version 1.2.2 (Applied Biosystems).  The DNA in each sample was quantified by 
interpolation of its threshold cycle (Ct) value from a standard curve of Ct values, which 
were created from a serially diluted cDNA mixture of all samples. The calculated quantity 
of the target gene for each sample was divided by the average sample quantity of the 
housekeeping genes, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
hydroxymethylbilane synthase (HMBS) to obtain the relative gene expression. All 
oligonucleotide primers were synthesized by Integrated DNA Technologies (Coralville, 
IA). Primers for HMBS and GAPDH were as described (48). Primers for CDH1 were: 
CDH1-F, 5’-GGAGGAGAGCGGTGGTCAAA-3’; CDH1-R, 5’-
TGTGCAGCTGGCTCAAGTCAA-3’.   
Immunofluorescence 
H16N2 cells were grown using chamber slides (Nunc, Rochester, NY) and 
infected with either control or EZH2 virus for cell line co-immunostaining with EZH2 
and E-cadherin antibody.  Forty-eight hours post-infection, the slides were washed with 
PBS, and were fixed using ice cold methanol.  Following an additional PBS wash, the 
slides were blocked for two hours using 5% donkey serum in PBS-T (phosphate buffered 
saline, 0.05% Tween-20). A mixture of rabbit anti-E-cadherin antibody (Labvision, 
Fremont, CA) and mouse anti-EZH2 antibody (BD Biosciences, San Jose, CA) were 
added to the slides at 1:250 and 1:100 dilutions, respectively, and incubated overnight at 
4° C.  Following an additional wash, the slides were incubated with Alexa 555-
conjugated goat, anti-rabbit antibody and Alexa 488-conjugated goat, anti-rabbit 
secondary antibody (Invitrogen) for one hour in the dark at room temperature.  After 
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washing, the slides were mounted using Vectashield mounting medium containing DAPI 
(Vector Laboratories, Burlingam, CA). 
Breast tissues samples were collected with informed consent and prior 
institutional review board approval. To prepare for tissue section staining, paraffin-
embedded breast tissue slides were soaked in xylene for one hour removal of paraffin. 
Slides were placed in citrate buffer (pH 6.0) and heated under pressure for 15 minutes for 
antigen retrieval. They were then blocked in PBS-T with 5% normal donkey serum for 
one hour. A mixture of rabbit anti-E-cadherin antibody (Labvision) and mouse anti-EZH2 
antibody (BD Biosciences) was added to the slides at 1:250 and 1:100 dilutions 
respectively and incubated overnight at  4° C. Slides were then incubated with secondary 
antibodies for one hour (anti-mouse IgG horse radish peroxidase conjugate and anti-
rabbit Alexa 555, both at 1:1000 dilution). Following a wash, fluorescently-labeled 
tyramide (Aelxa Fluor 488, Invitrogen) was added and the slides incubated for 10 
minutes at room temperature. They were washed and then mounted using Vectashield 
mounting medium. Confocal images were taken with a Ziess LSM510 META imaging 
system using Argon and Helium Neon 1 and Helium Neon 2 light source (Carl Zeiss, 
Thornwood, NY). The color images were exported as TIFF images. 
Luciferase Assay 
E-cadherin regulation by EZH2 was examined using the E-cadherin promoter 
luciferase reporter gene and transient transfection assays were performed. The breast cell 
lines H16N2, MCF10A and HME were transfected with wild-type or E-box mutant E-
cadherin luciferase construct (kind gift of Dr. Eric Fearon) as well as pRL-TK vector as 
internal control for luciferase activity, then subsequently infected with either EZH2 or 
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control viruses. Following two days of incubation, the cells were lysed and luciferase 
assays conducted using the dual luciferase assay system (Promega, Madison, WI). Each 
experiment was performed in triplicate. Using siRNA duplex, an EZH2 knockdown was 
performed in the invasive prostate cell line DU145.  Both were simultaneously 
transfected with E-cadherin promoter-luciferase reporter constructs, and the luciferase 
activity was measured after two days as previously described. 
Chromatin immunoprecipitation (ChIP) Assay 
ChIP experiments were carried out as described by Yu, et al.(49). For each ChIP 
assay, 5ug of antibodies were used; EZH2 (BD Biosciences), SUZ12 (Abcam, Cambridge, 
MA), EED,  trimethyl H3-Lys27 and acetyl H3 (Upstate), Myc (Abcam) or IgG control 
(Santa Cruz). Approximately 2-5 ul of ChIP-enriched chromatins were subjected to a 
standard ChIP-PCR reaction, and the enrichment of specific genomic regions was 
assessed relative to either control IgG or control cells. Each ChIP experiment was 
repeated at least three times. For ChIP with human tissues, ChIP-enriched DNA and input 
DNA were amplified through ligation-mediated PCR. Equal amounts (50ng) of amplified 
ChIP DNA and input DNA were subjected to PCR. Enrichment by ChIP was assessed 
relative to the input DNA and normalized to the level of GAPDH.  The primers used in 
the ChIP experiments were designed to flank the promoter regions of CDH1 and the 
WNT1 positive control gene, as well as the intragenic region of the NUP214 negative 
control. The sequences of the primers were: CDH1-pF, TAGAGGGTCACCGCGTCTAT; 
CDH1-pR, TCACAGGTGCTTTGCAGTTC; WNT1-pF1, 
ACCCGTCAGCTCTCGGCTCA; WNT1-pR1, TGCAGTTGCGGCGACTTTGG; 
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NUP214_pF1, CAGTGAGGTCTCAGCATCAGCA; NUP214_pR1, 
CTGGAGGCTATGGGGGTACTTG. 
Bisulfite Modification and Methylation-Specific PCR of CDH1 promoter. H16N2 
cells were infected with vector control or EZH2 adenovirus for 48hrs and genomic DNA 
was isolated (Qiagen). The genomic DNA was modified by sodium bisulfite treatment 
using the CpGenomeTM DNA Modification Kit (S7820, Chemicon, Temecula, CA). The 
DNA promoter methylation status of E-cadherin gene was investigated by PCR using 
primers specific to methylated and unmethylated promoters using the CpG WIZTM E-
cadherin Amplification Kit (S7804, Chemicon). The methylated and unmethylated 
control DNA (provided in the S7804 kit, Chemicon) were also subjected to bisulfite DNA 
modification and PCR analysis, and serves as positive controls for methylated and 
unmethylated DNA respectively. H2O was used as negative control for the PCR reaction. 
 
Results and Discussion 
Alteration in EZH2 expression changes the invasive phenotype of the cells. 
We have reported previously that EZH2 expression is increased in aggressive prostate 
and breast cancer (28, 29). Herein, we evaluated the effect of EZH2 overexpression in 
multiple primary and non-invasive prostate and breast cells.   A modified Boyden 
chamber assay was used to determine if primary prostate epithelial cells and 
immortalized breast cell lines (with very low endogenous EZH2 expression) undergo 
invasion upon ectopic over-expression of EZH2.  Primary cells and immortalized benign 
epithelial cell lines infected with an EZH2-encoding adenovirus, but not a control 
adenovirus, induced cell invasion (Fig. 3.1A).  Importantly, a truncated mutant  version 
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of EZH2 (EZH2∆SET, missing the C-terminal SET domain that is required for 
methyltransferase activity) did not induce invasion.  Additionally, EZH2-mediated 
invasion could be attenuated by incubating cells with the histone deacetylase (HDAC) 
inhibitor, SAHA, across all of the primary cultures and cell lines tested (Fig. 3.1A).  This 
suggests a role for histone deacetylation in EZH2-mediated effects.   
To expand our investigations, we explored whether perturbation of endogenous 
EZH2 would affect the invasiveness of cancer cell lines.  For these studies, we employed 
the highly invasive prostate cancer cell line DU145. Over-expression of EZH2∆SET in 
DU145 cells markedly reduced their invasive potential (Fig. 3.1B), suggesting that this 
mutant version of EZH2 functioned as a dominant negative.  Similarly, when EZH2 
levels were depleted using siRNA duplexes (Fig. 3.1C) or shRNA (Fig. 3.1D), there was 
marked attenuation of DU145 invasive potential.  
EZH2 regulates E-cadherin transcript and protein expression.  As earlier 
studies from our group suggested an inverse relationship between EZH2 and E-cadherin 
expression in prostate cancer (50), we hypothesized that EZH2 might regulate E-cadherin 
in the neoplastic process.  We infected an immortalized benign breast epithelial cell line, 
H16N2, with EZH2, EZH2∆SET, and control adenoviruses to determine whether EZH2 
represses expression of the E-cadherin mRNA transcript.  As hypothesized, EZH2 
overexpression resulted in abrogation of E-cadherin transcripts as confirmed by two 
independent methods; Northern blot analysis (Fig. 3.2A) and quantitative PCR (Fig. 
3.2B). Mutant EZH2 (EZH2∆SET) or EZH2-infected cells treated with SAHA did not 
show down regulation of E-cadherin, indicating the importance of the SET domain of 
EZH2 as well as HDAC activity. The effect of EZH2 overexpression on E-cadherin 
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protein was examined in four cell lines or primary cultures (H16N2, HME, MCF10A, and 
PrEC). We observed marked attenuation of E-cadherin protein levels by EZH2 
overexpression, but not EZH2∆SET, nor when EZH2 overexpressing cells were treated 
with HDAC inhibitor SAHA (Fig. 3.2C).  Immunoblot analysis also showed that E-
cadherin repression is dependent on the expression of EZH2; higher EZH2 expression 
resulting in increased E-cadherin repression (Fig. 3S1). Interestingly, a panel of breast 
and prostate cell lines showed an inverse correlation of EZH2 and E-cadherin protein 
expression (Fig. 3.2D), suggesting that PRC2 may be regulating E-cadherin levels in vivo.  
Similarly, this inverse association between EZH2 and E-cadherin protein levels was 
recapitulated in situ in both H16N2 breast epithelial cells (Fig. 3.2E) as well as in breast 
tumors (Fig. 3.2F).  
E-cadherin expression can rescue EZH2 mediated invasion. To determine if E-
cadherin loss is a significant factor in the downstream regulation of EZH2-mediated 
invasion, we re-introduced E-cadherin under the regulation of a CMV promoter. We 
assessed the possibility that this might counteract the effects or EZH2-mediated silencing 
of E-cadherin. While H16N2 cells infected with EZH2 adenovirus were highly invasive 
and exhibited strong repression of E-cadherin (Fig. 3.1A and 3.2A), this was attenuated 
by overexpression of E-cadherin under a non-EZH2 repressible promoter (i.e., CMV) 
(Fig. 3.3A).  To confirm that the loss of E-cadherin was a critical step in conferring 
invasiveness to H16N2 cells, E-cadherin was depleted using siRNA duplexes. H16N2 
cells treated with siRNA against E-cadherin acquired invasive potential (Fig. 3.3B), 
while control siRNA did not show this phenotype. 
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EZH2 regulates the E-cadherin expression by methylating the histone H3 lysine 27 
at the promoter region.   To determine if EZH2 can repress its activity, we performed a 
luciferase assay with an E-cadherin promoter-luciferase reporter construct  that contained 
an endogenous regulatory region of E-cadherin 1.4 KB upstream (51).  As predicted, 
EZH2 inhibited the activity of the transfected E-cadherin promoter-reporter across all 
three cell lines tested (Fig 3.4A).  EZH2-mediated repression of the E-cadherin promoter 
was blocked by SAHA, highlighting the role of histone deacetylation during EZH2-
mediated E-cadherin regulation.  Interestingly, the E-cadherin-luciferase reporter was 
slightly induced by expression of EZH2∆SET (Fig. 3.4A), which suggested a dominant, 
negative effect.  Knockdown of EZH2 in DU145 cells led to increased activity of the 
transfected E-cadherin promoter-reporter construct (Fig. 3.4B).  
In order to determine the minimal region of the E-cadherin promoter required  for 
EZH2-mediated repression, we tested mutant E-cadherin promoter-luciferase reporters 
(19) including Ecad-EboxA.MUT-luc (mutated Ebox A), Ecad-EboxC.MUT-luc 
(mutated Ebox C), Ecad-EboxABC.MUT-luc (all the three E-boxes, A, B and C are 
mutated) as well as wild-type E-cadherin promoter-luciferase reporter.  While EZH2 
repressed the wild-type E-cadherin promoter activity, none of the E-boxes mutants tested 
were inhibited, indicating that the wild type E-cadherin promoter is required for EZH2 
mediated E-cadherin repression (Fig. 3S2).  
Ectopically overexpressed, myc-tagged EZH2 assembles endogenous PRC2 
components including SUZ12 and EED, as demonstrated by their presence in anti-myc 
immunoprecipitates (Fig. 3.4C). Addition of SAHA did not inhibit the binding of PRC2 
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complex members, indicating that the HDAC inhibitors do not inhibit PRC2 protein-
protein interactions. 
The polycomb group proteins are known to bind to a selected group of target 
genes and inhibit transcription (44, 45). To determine whether the endogenous PRC2 
complex binds to the E-cadherin gene promoter, we carried out chromatin 
immunoprecipitation (ChIP) assay using antibodies specific to the PRC2 components 
and to the histone modifications.  The invasive prostate cancer cell line DU145, which 
expresses high level of EZH2 (Fig. 3.2D), was used to test complex formation by 
endogenous EZH2 and other PRC2 complex members. These investigations indicated 
binding of EZH2, SUZ12, and EED to the E-cadherin promoter (Fig. 3.4D). 
Additionally, histone H3 was found to be trimethylated at lysine 27 on the E-cadherin 
promoter. Of particular importance was the finding that the HDAC inhibitor SAHA, 
while increasing histone acetylation as expected, markedly reduced PRC2 occupancy 
and H3K27 trimethylation on the E-cadherin promoter.  
As ectopic EZH2 assembles the PRC2 complex (Fig. 3.4C), we explored the 
possibility that it might recruit the PRC2 complex proteins to the E-cadherin promoter.  
The H16N2 immortalized breast epithelial cell line, which has low level of endogenous 
EZH2, was infected with either vector control or EZH2 adenovirus and examined for 
PRC2 occupancy on the E-cadherin promoter. Using an antibody against Myc epitope, 
tagged at both EZH2 and mutant EZH2 constructs, we confirmed that ectopically 
expressed EZH2 binds to the E-cadherin promoter by ChIP (Fig. 3.4E).   
Interestingly, ectopic over-expression of EZH2 recruited other PRC2 
components to the E-cadherin promoter and markedly increased H3K27 trimethylation 
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(Fig. 3.4E). The histone H3K27 trimethylation mark was used to assess PRC2 
occupancy at the E-cadherin promoter by a ChIP analysis in one localized prostate 
tumor and three metastatic prostate cancer tissues. Results indicated that the E-cadherin 
promoter contained high levels of H3K27 trimethylation in the three metastatic tumor 
specimens tested as compared to the localized prostate cancer tissue specimen (Fig. 
3.4F). Recently, it has been shown that DNA methyltransferases (DNMTs) and EZH2 
cooperate in silencing genes such as MYT1, WNT1, KCNA1 and CNR1 (39). Additional 
H3K9 methylation may lead to promoter CpG island DNA methylation (43). However, 
E-cadherin promoter methylation analyses of EZH2 over-expressing cells did not 
exhibit E-cadherin promoter DNA methylation. This indicated that histone 
trimethylation-mediated by EZH2 plays a major role in the silencing of E-cadherin. 
Thus, our data suggests a novel mechanism by which E-cadherin is down-
regulated in EZH2-overexpressing cells through histone H3K27 trimethylation at the E-
cadherin  promoter.  While EZH2 expression was low in benign epithelial tissues, the 
expression of EZH2 destabilized with tumor progression.   EZH2 expression became 
dysregulated concurrently with increased HDAC activity, which resulted in 
trimethylation of histone H3 lysine 27 at the E-cadherin promoter with subsequent 
repression of  expression (Fig. 3.4G). This enzymatic activity was inhibited, however, 
when the cells were treated with HDAC inhibitor despite overexpression of EZH2. 
A large body of evidence suggests that loss of E-cadherin expression is 
associated with the acquisition of invasiveness and advanced tumor stage for cancers of 
epithelial origin including prostate (52, 53), gastric (54), colon (55), and breast cancer 
(11, 56, 57). While several mechanisms have been proposed for the downregulation of 
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E-cadherin, our data suggest a novel mechanism whereby increased levels of EZH2 in 
aggressive tumors silence E-cadherin expression through histone H3K27 trimethylation.  
EZH2 regulates E-cadherin transcription by physically binding to its promoter. The 
expression of EZH2 recruits HDAC activity with removal of the acetyl group from the 
histone H3K27 at the promoter region of E-cadherin. This enables EZH2 to exert its 
histone methyltransferase enzymatic activity. Tri-methylation of histone H3 on lysine 
27 leads to compaction of chromatin and blocks transcription factors from binding and 
initiating transcription.  EZH2 may mediate increased invasiveness and metastasis by 
silencing a number of downstream targets in addition to E-cadherin. 
 Interestingly, we demonstrated that HDAC inhibitors inhibited the function of 
EZH2 and prevented the EZH2 mediated downregulation of E-cadherin and reduced the 
invasion, thus suggesting a mechanism for these anti-cancer drugs. Our findings 
suggest that EZH2 may be a viable target for therapeutic inhibition in aggressive 
tumors of epithelial origin.  
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Figure 3.1. Over expression of EZH2 enhances invasion. A, Ectopic expression of 
EZH2 induces invasion of primary prostate epithelial cells and benign immortalized 
breast cell lines. A reconstituted basement membrane invasion chamber assay (Boyden 
chamber assay) was used to assess the invasive potential of primary prostate and benign 
breast epithelial cell lines infected with EZH2, EZH2∆SET or control adenovirus.  EZH2 
infected cells were also treated with the histone deacetylase inhibitor SAHA.  
Representative fields of invaded and stained cells are shown (left). Invasion was 
quantitated using colorimetry (absorbance at 560 nm, right). All p values were calculated 
between EZH2 and vector treated samples. B, The SET domain mutant of EZH2 inhibits 
cancer cell invasion. DU145 cells, which express high levels of endogenous EZH2, were 
infected with EZH2, EZH2∆SET, and control adenoviruses. Invasion was quantitated 
using colorimetry. The p value was calculated between EZH2∆SET and vectors. C, Cell 
invasion is attenuated by EZH2 knockdown. Boyden chamber invasion assay using 
DU145 cells treated with siRNA duplexes targeting EZH2. Inset demonstrates 
knockdown of EZH2 protein by RNA interference. All p values were calculated between 
control and EZH2 knockdown clones. D, Stable knockdown of EZH2 decreases 
invasiveness of DU145 cells. DU145 cells were stably transfected with EZH2 shRNA 
and assessed by invasion assay. Three stable clones exhibiting knockdown of EZH2 are 
shown. Inset demonstrates knockdown of EZH2 protein by RNA interference. 
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Figure 3.2. EZH2 mediates repression of E-cadherin transcript and protein. A, 
Northern blot analyses of the E-cadherin gene in EZH2 over expressing cells. Northern 
blot analysis was carried out using the RNA from H16N2 cells infected with EZH2 and 
control adenovirus. EZH2, E-cadherin and GAPDH probes were labeled with p32dCTP 
and hybridized to the blots. Note that uninfected H16N2 cells do not express EZH2, 
while E-cadherin is expressed at high levels in these cells. B, Quantitative SYBR green 
RT-PCR of EZH2 transcript in cell lines infected with EZH2 and control adenoviruses. 
RT-PCR on each sample was performed in duplicate, and a ratio was calculated relative 
to the housekeeping genes GAPDH and hydroxymethylbilane synthase (HMBS). C, 
Immunoblot analysis of EZH2 and E-cadherin in breast cell lines H16N2, MCF10A, 
HME and primary prostate cell PrEC infected with EZH2, EZH2∆SET mutant, and 
control adenovirus infected cells as well as EZH2 infected cells treated with SAHA.  β-
tubulin was included as a loading control. Experiments were performed multiple times 
and a representative immunoblot is shown. D, Immunoblot analysis of EZH2 and E-
cadherin in a panel of breast and prostate cell lines. The cultured lines include both 
invasive and non-invasive cells. β-tubulin was included as a loading control. Semi-
quantitation of EZH2 and E-cadherin in multiple cell lines is represented in a graphical 
format (top panel). E, Immunostaining of the breast cell line H16N2 infected with EZH2 
and control adenovirus. Green staining represents EZH2 protein, red staining represents 
E-cadherin, and blue represents nuclear staining with DAPI. Lower right panel shows a 
higher magnification image. F, Association between EZH2 and E-cadherin protein levels 
in human breast tumors by immunofluorescence.  Upper left panel shows invasive 
carcinoma of the breast with high EZH2 protein expression in the nuclei (green) and low 
E-cadherin expression (red), evidenced by a decrease in the membrane staining.  A 
normal lobule is present in the lower part of the figure. Top right panel shows the higher 
magnification of the normal lobule shown with crisp membrane staining for E-cadherin. 
EZH2 staining is absent in this region. The lower left panel shows invasive carcinoma 
with foci of high EZH2 expression.  The lower right panel shows higher magnification of 















Figure 3.3. E-cadherin over-expression attenuates EZH2-mediated cell invasion.  A, 
H16N2 cells were transfected with E-cadherin or vector alone. Transfected cells were 
infected with EZH2, EZH2∆SET, and control adenovirus. Cell invasion was assessed by 
Boyden chamber assay, and p values were calculated between EZH2 and EZH2+E-
cadherin samples. B, E-cadherin knockdown in H16N2 cells was carried out using siRNA 
duplex. siRNA targeting luciferase served as a control. The p values were calculated 
between Luciferease RNAi and EZH2 RNAi samples. The inset demonstrates 



















Figure 3.4. Regulation of the E-cadherin promoter by EZH2.  A, Benign breast cell 
lines H16N2, MCF10A and HME were transfected with an E-cadherin-luciferase 
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promoter construct and infected with either EZH2, EZH2∆SET or control adenovirus. 
EZH2 infected cells were also incubated with SAHA.  Relative luciferase activity (RLA) 
was assessed. B, Knockdown of EZH2 in DU145 cells induces E-cadherin promoter 
activity. EZH2 expression was inhibited by RNA interference in DU145 cells that were 
transfected with the E-cadherin promoter-luciferase construct.  The p value was 
calculated between EZH2 RNAi and scrambled RNAi samples. C, Ectopically expressed 
EZH2 functions in a complex with endogenous PRC2 components SUZ12 and EED. 
H16N2 cells were infected with myc-tagged EZH2 adenovirus. Immunoprecipitation was 
carried out using anti-myc antibody, and subsequent Western blotting performed with 
either SUZ12 or EED antibody. D, The endogenous PRC2 complex is recruited to the E-
cadherin promoter. ChIP was carried out using antibodies against EZH2, EED, SUZ12, 
trimethyl-histone H3-Lys27 (3mH3K27), acetyl histone H3 (Ac-H3) and IgG control. 
Addition of SAHA curtails the recruitment of these complexes to the E-cadherin 
promoter, while acetylated histone levels increase at the E-cadherin promoter. Each ChIP 
experiment was repeated at least three times and a representative experiment is shown. E, 
Ectopically expressed EZH2 binds the E-cadherin promoter and leads to H3K27 
trimethylation. ChIP was carried out in H16N2 cells infected with EZH2 or control 
adenovirus and assayed by PCR analysis. The upper panel shows that using Myc 
antibody, which is the epitope tag in the EZH2 constructs, myc-EZH2 is found to bind 
the E-cadherin promoter. The lower panel showed by qPCR that EZH2 and 3mH3K27 
co-occupy the E-cadherin promoter in the EZH2-overexpressing H16N2 cells. Error bar: 
n = 3, mean ± SEM. F, The E-cadherin promoter is trimethylated at histone H3K27 in 
metastatic prostate cancer tissues. ChIP experiments were performed using anti-
3mH3K27 antibody in one localized prostate tumor and three independent metastatic 
prostate tumors. ChIP-enriched DNA and the input DNA were first amplified through 
ligation-mediated PCR. Equal amounts (50ng) of amplified ChIP DNA and the input 
DNA were then subjected to PCR, and enrichment by ChIP was assessed relative to the 
input DNA, then normalized to the level of GAPDH. Error bar: n = 3, mean ± SEM. G, A 
model depicting the mechanism of EZH2 mediated E-cadherin repression.  In benign 
cells the E-cadherin promoter is not occupied by PRC2 complex. In cancer, the increased 
expression of PRC2 leads to tight binding to the promoter of E-cadherin, followed by 
deacetylation of histone H3 and subsequent trimethylation of lysine 27.  This leads to 
repression of E-cadherin expression. Addition of HDAC inhibitors prevents the first step 

















Figure 3S1. The repression of E-cadherin increases with EZH2 increases. Benign 
breast cell line H16N2 was infected with EZH2 by 0 MOI, 0.1 MOI, 1 MOI, 10 MOI, 
100MOI or 1000MOI. EZH2 and E-cadherin level were examined by immunoblot. β-









Figure 3S2. E-boxes of E-cadherin are necessary for EZH2 to repress E-cadherin 
promoter activity.  Benign breast cell line HME was transfected with E-cadherin 
promoter luciferase construct wild-type or mutants and infected with either EZH2, 
EZH2∆SET or control adenovirus. EZH2 infected cells were also incubated with SAHA.  
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A CAUSAL ROLE FOR MICRORNA-101 IN UPREGULATING EZH2 IN 
AGGRESSIVE TUMORS 
 
Recent studies have shown that histone H3 lysine 27 trimethylation, which is 
mediated by EZH2 on the promoters of the EZH2 target genes, leads to silencing of gene 
expression(1).  Our previously studies demonstrated that EZH2 is upregulated in 
aggressive prostate and breast tumors(2,3).  Also multiple studies showed that EZH2 is 
overexpressed in other aggressive tumors, including bronchial cancer(4), melanoma(5), 
bladder cancer(6), liver cancer(7), as well as in vitro cancer cell lines(8) .    
Functional studies have demonstrated that EZH2 is a bona fide oncogene. 
Knock-down of EZH2 protein by RNA interference results in growth arrest in prostate 
cancer cells (2), myeloma cells (9) as well as TIG3 fibroblasts(10). By contrast, ectopic 
overexpression of EZH2 promotes cell proliferation and invasion in vitro (3,10,11), and 
induces xenograft tumor growth in vivo(10). A wide varsity of studies revealed that the 
C-terminal SET domain which possesses the histone methyltransferase activity, is 
essential for EZH2 to perform its oncogenic functions, indicating that histone 
modification and epigenetic silencing play an important role during cancer progression. A 
recent study demonstrated that E2F6 complex contains EZH2 in proliferating cells, 
suggesting that this complex may be involved in regulating genes required for cell cycle 
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control(12).  Several mechanisms have been proposed to illuminate the regulation of 
EZH2, including the pRB-E2F pathway and amplification(13), as well as repression by  
tumor suppressor p53(14).  However there is no clear cut mechanism that has been 
implicated in overexpression of EZH2 in tumors. We here investigated the possibility of 
EZH2 regulation by microRNAs. 
MicroRNAs are a type of regulatory, non-coding, endogenous RNAs that have 
recently gained considerable attention and have been implicated in regulating diverse 
cellular processes. MicroRNAs are 18-24 nucleotides in length and are proposed to 
regulate gene expression through translational repression by binding to the 3’-UTR 
(untranslated region) of target mRNAs(15). They are also proposed to regulate gene 
expression by mRNA cleavage, and mRNA decay initiated by miRNA-guided rapid 
deadenylation (16).  miRNAs are abundant, highly conserved molecules and predicted to 
regulate a large number of transcripts. To date the international miRNA Registry 
database (http://microrna.sanger.ac.uk) has more than 800 human identified 
microRNAs(17) and their total number in humans has been predicted to be as high as 
1,000(18). A large number of microRNAs exhibit tissue-specific expression(19)  and 
defined to be either tumor suppressors or oncogenes (20,21), playing a crucial role in 
variety of cellular processes such as cell cycle control, apoptosis, haematopoiesis as well 
as the dysregulation of several miRNAs are demonstrated to play a significant role in 
human disease processes including tumorigenesis(22). Several microRNAs are located in 
the region of hot spots for chromosomal abnormalities 23,24. This results in abnormal 
expression of miRNAs which affect cellular functions. 
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Recent studies indicate that multiple miRNAs may play a role in human 
cancer pathogenesis. For example, deletions or mutations in genes that encode miRNA 
tumor suppressors might lead to loss of a miRNA or miRNA cluster, and thereby 
contribute to oncogene deregulation (21,25). Large-scale miRNA profilings of normal 
and cancer tissues suggest that a number of microRNAs are either overexpressed or 
downregulated in tumors (26,27).  It has been shown that miRNA genes are frequently 
located in cancer-associated genomic regions or fragile sites(24). The genes encoding 
mir-15 and mir-16 are located at chromosome 13q14, a region that is deleted in the 
majority of B-cell chronic lymphocytic leukemias (B-CLL) suggesting that mir-15 and 
mir-16 may possibly function as tumor suppressors.  let-7 miRNA family members are 
known to down regulate the oncogene RAS(28).  Its expression is reduced in tumors 
which in turn contributes to the elevated activity of the RAS pathway(27). Expression 
levels of miR-143 and miR-145 were decreased in colon cancer tissues as well as in 
cancer cell lines(29). In contrast, several microRNAs are upregulated in cancer which 
may function as oncogenes. Members of the miR-17 cluster provide an oncogenic 
function via their upregulated expression by c-Myc leading to effects on downstream 
genes which are mediators of cell cycle and apoptosis events(30). Many microRNAs play 
a role during development and tissue differentiation(31). miR-181, a microRNA that is 
strongly upregulated during differentiation, participates in establishing the muscle 
phenotype. Recent studies demonstratedt that miR-181 down regulates the homeobox 
protein Hox-A11(32). Similarly miR-196 is involved in regulating HOXB8(33), 
confirming the significant roles played by microRNA during developmental processes. 
Furthermore, it has been shown recently that microRNA 10b is involved in breast cancer 
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metastasis(34) . Huang et al by using  genetic screen using a nonmetastatic, human breast 
tumour cell line that was transduced with a miRNA-expression library found that miR-
373 and miR-520c promote tumor invasion and metastasis(35). 
 
Interestingly a recent study from Lim et al., (36) showed that a few 
microRNAs can regulate large number of target mRNA and their studies also indicated 
that the miRNA can downregulate not only the proteins, but the transcript level of the 
target mRNA. In this present study we explored the possible by which microRNAs 
dysregulate EZH2 expression. Here we identified a role of miR101 in regulating EZH2 
expression in tumors as well as implicate a deletion or loss of heterozygosity in miR101 
genomic localization as the cause for EZH2 upregulation. 
 
Results and Discussion 
microRNA 101 targets EZH2.  Our previous studies demonstrated that 
EZH2 expression is increased in aggressive prostate and breast cancer. Several other 
studies later reported overexpression of EZH2 in several aggressive cancers. However the 
mechanism by which EZH2 is dysregulated during cancer progression is not clearly 
understood. In order to search for possible microRNAs that targets EZH2, we utilized 
four target prediction databases- PicTar, Microinspector, miRanda and TargetScan (Fig 
4.1a). Mir101 and miR217 were recognized as top two which target to EZH2 in all the 
target prediction sites (Fig 4.1b). Bioinformatical analysis indicated that hsa-miR101 has 
two binding sites on EZH2 3’UTR region of EZH2 (Fig 4.1c).  To examine whether hsa-
miR101 could interact with the 3’UTR of EZH2, we generated luciferase reporters with 
3’UTR or complementary 3’UTR of EZH2. We observed that overexpression of hsa-
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miR-101 but not the control microRNA (hsa-miR-16) decreased activity of luciferase 
with 3’UTR of EZH2 (Fig. 4.1d), while the activity of luciferase with complementary 
3’UTR of EZH2 was not altered by hsa-miR-101. This indicates that hsa-miR-101 indeed 
binds to 3’UTR of EZH2 and represses EZH2 expression. 
 
microRNA101 downregulates both EZH2 transcript and protein. Since 
hsa-miR-101 could interact with 3’UTR of EZH2, we examined if the EZH2 transcript 
and protein levels can be repressed by miR101 overexpression. As shown in figure 4.2a, 
precursor of miR101 but not control microRNAs reduces the EZH2 transcripts. Similarly, 
immunoblot analysis using EZH2 specific antibody demonstrated that miR101 
downreagulates EZH2 protein expression in prostate cell line DU145 as well as breast 
cell line SKBr3 which have high endogenous EZH2 expression (Fig 4.2b). Interestingly, 
another predicted target of hsa-miR-101, N-Myc was not repressed by hsa-miR-101 
overexpression (Fig 4.2c), indicating that miR101 might specifically downregulates 
EZH2. Importantly, similar to the effect of siRNA against EZH2, the other polycomb 
group members EED and SUZ12 expression were significantly decreased because of hsa-
miR-101 overexpression in SKBr3 and DU145 (Fig 4.2d), suggesting hsa-miR-101 
downregulates not only EZH2 but also the other members of PRC2. Furthermore, when 
low endogenous EZH2 expression breast cell line HME was treated with anti-miR-101, 
EZH2 expression was upregulated, confirming that hsa-miR-101 indeed regulates EZH2 
expression(Fig 4.2e). Additionally, when the non-invasive HME cells were treated with 




microRNA101 reduces cell growth, invasion and tumor formation. Our 
earlier studies have shown that down regulating the EZH2 expression  by RNA 
interference results in reduced cell growth as well decreases invasion, we hypothesized 
that hsa-miR-101 will induce similar phenotype. In hsa-miR-101 overexpressed SKBr3 
cells, E-cadherin (and other EZH2 targets) expression is increased (Fig 4.3a).  Similar to 
the effect of siRNA against EZH2, overexpression of hsa-miR-101 reduced the cell 
growth (Fig 4.3b) to an extent similar to siRNA against EZH2. Furthermore, 
overexpression of hsa-miR-101 or siRNA against EZH2 in highly invasive cell line 
SKBr3 significantly decreased the invasive potential of cells, suggesting function of 
EZH2 is inhibited by hsa-miR-101 (Fig 4.3c). 
To address the role of hsa-miR-101 in tumor formation, we generated DU145 
cells which stably express hsa-miR-101, and injected it or control cells into nude mice. 
The vector control stable DU145 formed tumors whose size increased dramatically (Fig 
4.3d). However, DU145 stably expressing hsa-miR-101 formed the tumors slowly and 
the size of tumors was much smaller compared to vector control. This finding suggests 
that hsa-miR-101 plays an important role in tumor formation through the regulation of 
EZH2. In order to test if hsa-miR-101 could de-repress the targets of EZH2, we 
performed chromatin immunoprecipitation analysis. When hsa-miR-101 was 
overexpressed, the binding of EZH2 to the promoters of WNT1 and CNR1, which are 
known as the targets of EZH2, was reduced significantly compared to the binding to a 
non specific control, Actin (Fig 4.3e).  Since EZH2 knockdown by siRNA and hsa-miR-
101 have similar functional and phenotypic effects, we hypothesized that the global gene 
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expression regulation by both treatment will have significant overlap. In order to test this, 
we performed gene expression analysis by cDNA microarray from the cell lines treated 
with siRNA against EZH2 or hsa-miR-101. As shown in Fig 4.3f, there was a significant 
overlap between the genes dysregulated by hsa-miR-101 and siRNA against EZH2. 
miR101 has the opposite expression pattern to that of EZH2 in tumors 
and show deletion or loss of heterzygosity. In order to test the expression of hsa-miR-
101 in tumors, we utilized total RNA from the normal, prostate tumor and metastatic 
prostate tissues to perform qRT-PCR. EZH2 and hsa-miR-217 expression in 
corresponding tissues were also examined. While hsa-miR-101 expression is decreased 
from normal to tumor tissue with lowest expression in metastatic tissue, the EZH2 
expression showed opposite pattern (Fig 4.4a) indicating supporting our hypothesis that 
miR101 indeed regulates the EZH2 expression in tissues. However, hsa-miR-217 did not 
show significant alteration in expression between normal and cancer tissue.  Furthermore, 
to test the mechanism by which hsa-miR-101 expression is dysregulated and 
consequently leads to upregulation of EZH2, we performed genomic DNA relative 
quantitation of miR101 locus. The result indicates that most of tissues with high EZH2 
overexpression show a deletion or copy loss of hsa-miR-101 chromosome location (Fig 
4.4b), suggesting a novel mechanism by which EZH2 is dysregulated in metastatic 
cancers. 
Thus, our data suggests a novel mechanism by which hsa-miR-101 represses 
the expression of histone methyltransferase EZH2. In normal tissues, hsa-miR-101 
chromosome location is intact, and EZH2 expression is too low to detect. However, 
once the chromosome location of hsa-miR-101 is mutated or deleted, the decrease of 
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hsa-miR-101 expression will result in upregulating EZH2 expression and promote cell 
invasion and tumoregenesis. 
 
Materials and method 
Luciferase Assay. The 3’-UTR or complementary sequence of 3’-UTR of 
EZH2were cloned into pMIR-REPORT™ miRNA Expression Reporter Vector (Ambion). 
SKBr3 cells were pre-transfected with pre-hsa-miR-101 or controls and then 
co-transfected with 3’-UTR-luc or complementary 3’-UTR-luc, as well as pRL-TK 
vector as internal control for luciferase activity. Post 48 hours of incubation, the cells 
were lysed and luciferase assays conducted using the dual luciferase assay system 
(Promega, Madison, WI). Each experiment was performed in triplicate.  
Small RNA interference and microRNA transfection. The knockdown of 
EZH2 was accomplished with siRNA duplex (Dharmacon, Lafayette, CO) as previously 
described (2). Precursors of microRNA and negative control were purchased from 
Ambion (Austin, TX). Antagomir-101 and negative control were purchased from 
Dharmacon. Transfection were performed with oligofectamine (Invitrogen, Carlsbad, CA) 
or lipofectamine (Invitrogen). 
SYBR Green Quantitative Real-Time PCR. Total RNA was isolated from 
SKBr3 and DU145 cells that were transfected either with pre-hsa-miR-101, or control 
precursors (Qiagen). Quantitative PCR (QPCR) was performed using SYBR Green dye 
on an Applied Biosystems 7300 Real Time PCR system (Applied Biosystems, Foster 
City, CA).  Briefly, 1 µg of total RNA was reverse transcribed into cDNA using 
SuperScript III (Invitrogen, Carlsbad, CA) in the presence of random hexamers and oligo 
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dT primers (Invitrogen).  All reactions were performed in duplicate with SYBR Green 
Master Mix (Applied Biosystems) plus 25 ng of both the forward and reverse primer 
according to the manufacturer’s recommended thermocycling conditions,  then subjected 
to melt curve analysis. Threshold levels for each experiment were set during the 
exponential phase of the QPCR reaction using Sequence Detection Software version 
1.2.2 (Applied Biosystems).  The DNA in each sample was quantified by interpolation of 
its threshold cycle (Ct) value from a standard curve of Ct values, which were created from 
a serially diluted cDNA mixture of all samples. The calculated quantity of the target gene 
for each sample was divided by the average sample quantity of the housekeeping genes, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to obtain the relative gene 
expression. All oligonucleotide primers were synthesized by Integrated DNA 
Technologies (Coralville, IA).  
Immunoblot Analyses. The breast cancer cell lines SKBr3 and prostate 
cancer cell DU145 were transfected with pre-hsa-miR-101 or controls. The breast cell 
lines H16N2 and HME, as well as normal prostate epithelial cells PrEC were transfected 
with antagomiR-101 or negative controls. Post 72 hours transfection, cells were 
homogenized in NP40 lysis buffer (50 mM Tris-HCl, 1% NP40, pH 7.4, Sigma, St. Louis, 
MO), and complete proteinase inhibitor mixture (Roche, Indianapolis, IN). Ten 
micrograms of each protein extract were boiled in sample buffer, separated by SDS-
PAGE, and transferred onto Polyvinylidene Difluoride membrane (GE Healthcare). The 
membrane was incubated for one hour in blocking buffer [Tris-buffered saline, 0.1% 
Tween (TBS-T), 5% nonfat dry milk] and incubated overnight at  4ºC with the following:  
anti-EZH2 mouse monoclonal (1:1000, 1:5000 in dilution buffer, BD Biosciences, San 
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Jose, CA), anti-EED rabbit polyclonal (1:1000 in dilution buffer, Upstate, Charlottesville, 
VA),  anti-SUZ12 rabbit polyclonal (1:1000 in dilution buffer, Upstate, Charlottesville, 
VA), and anti-N-myc rabbit polyclonal antibodies (1:1000 in dilution buffer, Santa Cruz).  
Following a wash with TBS-T, the blot was incubated with horseradish peroxidase-
conjugated secondary antibody and the signals visualized by enhanced 
chemiluminescence system as described by the manufacturer (GE Healthcare). The blot 
was re-probed with β-tubulin for confirmation of equal loading. 
Basement Membrane Matrix Invasion Assay. For invasion assays, the 
breast cell lines H16N2 and HME, as well as normal prostate epithelial cells (PrEC, 
Cambrex, East Rutherford, NJ), were transfected with antagomiR-101 or negative 
controls. Invasive breast cancer cell SKBr3 and prostate cancer cell DU145 were 
transfected with pre-hsa-miR-101 or controls. Forty-eight hours post-transfection, cells 
were seeded onto the basement membrane matrix (EC matrix, Chemicon, Temecula, CA) 
present in the insert of a 24 well culture plate. Fetal bovine serum was added to the lower 
chamber as a chemoattractant. After 48 hours, the non-invading cells and EC matrix were 
gently removed with a cotton swab. Invasive cells located on the lower side of the 
chamber were stained with crystal violet, air dried and photographed. They were then 
enumerated microscopically using multiple representative areas. For colorimetric assays, 
the inserts were treated with 150 µl of 10% acetic acid and the absorbance measured at 
560nm using a spectrophotometer (GE Healthcare Bio-Sciences Corp, Piscataway, NJ ). 
Cell Counting. Cells were plated to 24-well plates at desire cell concentration. 
After cells attach to the bottom, transfect cells with precursor microRNA or controls. At 
the measure time, wash the cells with PBS once and add 400ul 1X 0.05%Trypsin-EDTA, 
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incubate then aspirate to single cells. Add 200ul to 9.8ml Isotone, use the Z2 coulter 
counter to count cells. The final reading 1000 means 100,000 cells 
Chromatin immunoprecipitation (ChIP) Assay. ChIP experiments were 
carried out as described by Yu, et al.(49). For each ChIP assay, 5ug of antibodies were 
used; EZH2 (BD Biosciences), trimethyl H3-Lys27 (Upstate), or IgG control (Santa 
Cruz). Approximately 2-5 ul of ChIP-enriched chromatins were subjected to a standard 
ChIP-PCR reaction, and the enrichment of specific genomic regions was assessed relative 
to either control IgG or control cells. Each ChIP experiment was repeated at least three 
times. For ChIP with human tissues, ChIP-enriched DNA and input DNA were amplified 
through ligation-mediated PCR. Equal amounts (50ng) of amplified ChIP DNA and input 
DNA were subjected to PCR. Enrichment by ChIP was assessed relative to the input 
DNA and normalized to the level of Actin. 
Expression Profiling. Expression profiling was performed using the Agilent 
Whole Human Genome Oligo Microarray (Santa Clara, CA) according to the 
manufacturer's protocol. SKBr3 and DU145 cells were transfected with pre-hsa-miR-101 
or negative control for precursor microRNA. Over- and under-expressed signatures were 
generated by filtering to include only features with significant differential expression 
(Log ratio, P < .01) in all hybridizations and two-fold average over- or under-expression 
(Log ratio) after correction for the dye flip.  
Murine Prostate Tumor Xenograft Model. All procedures involving mice 
were approved by the University Committee on Use and Care of Animals (UCUCA) at 
the University of Michigan and conform to their relevant regulatory standards. Five-
week-old male nude athymic BALB/c nu/nu mice (Charles River Laboratory, 
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Wilmington, MA) were used for examining the tumorigenicity. To evaluate the role of 
miR-101 overexpression in tumor formation, the stable miR-101 overexpression DU145 
cells or the vector control cells were propagated and inoculated by subcutaneous injection 
into the dorsal flank of ten mice (n = 5 per group). Tumor size was measured every week, 
and tumor volumes were estimated using the formula (π/6) (L × W2), where L = length of 
tumor and W = width.  
qRT-PCR for miRNA for cell lines and tissue samples. Total RNA with 
small RNA was isolated from SKBr3 and DU145 cells that were transfected either with 
pre-hsa-miR-101, or control precursors. Dilute total RNA at 10ng/ul. For RT, make 
master mix of 0.15ul 100mM dNTPs, 1.00ul MultiScrible Reverse Transcriptase (50U/ul), 
1.50 10X Reverse Transcription Buffer, 0.188ul RNase Inhibitor (20U/ul) and 4.192ul 
Nuclease-free water. For each 15ul RT reaction, add 7ul of master mix, 5ul of RNA 
samples (10ng/ul) and 3ul 5X specific RT primer. Leaving the thermal cycler in the 9600 
Emulation mode, program the thermal cycler as follows: 16℃ for 30 minutes, 42℃ for 
30 minutes and 85℃ for 5 minutes. For each 20ul PCR reaction, mix Taqman 10ul 2X 
Universal PCR Master Mix (No AmpErase UNG), 6.67ul Nuclease-free water, 1ul 20X 
specific PCR primer and 1.33ul RT product. Leaving the thermal cycler in the 9600 
Emulation mode, program the thermal cycler as follows: 95℃ for 10 minutes, 40 cycles 
of 95℃ for 15seconds and 60℃ for 60seconds. Using the comparative CT method, we 
use endogenous control (RNU6B) to normalize the expression levels of target micro-




Figure 4.1. EZH2 is a target of hsa-miR-101. a. 4-way Venn diagram displaying 
miRNAs computationally predicted to target EZH2 by PicTar (blue), miRanda (red), 
TargetScan (green), and MicroInspector (orange). b. Ranking of binding sites that were 
predicted by three or more programs displayed relative to the score calculated by each 
respective program. The number in parenthesis represents miRNAs with multiple binding 
sites. c. Schematic of two predicted hsa-miR-101 binding sites in the EZH2 3’ UTR. d. 
Luciferase activity assay of EZH2 3’ UTR-luc constructs in the presence of hsa-miR-101 
and hsa-miR-16 relative to a control vector. 
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Figure 4.2.  hsa-miR-101 regulates EZH2 transcript and protein expression. a. 
hsa-miR-101 overexpression represses EZH2 mRNA expression in SKBr3 cells, 
while negative controls and unrelated microRNAs (hsa-miR-26a, hsa-miR-128a, 
and hsa-miR-16) did not inhibit EZH2 expression. b. Immunoblot analysis reveals 
downregulation of EZH2 protein in DU145 and SKBr3 cell lines by overexpression 
of hsa-miR-101, but not in hsa-miR-217 treated cells and negative controls. c. hsa-
miR-101 downregulates specifically EZH2 but not the other predicted target N-myc 
in SKBr3 cells. Several other unrelated precursor miRNAs (hsa-miR-26a, hsa-miR-
128a, hsa-miR-16 and hsa-miR-495) do not repress EZH2. d. Both EZH2 RNAi and 
hsa-miR-101 down regulate the PRC2 complex members EZH2, EED and SUZ12 
in comparison hsa-miR-217, a control siRNA, and negative pre-miRNA control. e. 
HME cells with low EZH2 expression are treated with antagomir-101 or negative 
control. AntagomiR-101 treated cells show clear up regulation of EZH2 protein.  f. 
AntagomiR-101 increases cell invasion. Non-invasive HME cells treated with 
antagomiR-101 attain invasive property. The negative control did not alter the non-










Figure 4.3.  hsa-miR-101 inhibits cell growth, and invasion and tumor growth. a. 
Overexpression of hsa-miR-101 results in upregulating genes which is repressed by 
EZH2. b. hsa-miR-101 (purple) or siRNA targeting EZH2 (green)  inhibit cell growth 
relative to the control miRNA (blue) and luciferase siRNA duplex (black). c. hsa-miR-
101 or EZH2-siRNA inhibits the invasive phenotype of the breast and prostate cell lines 
SKBr3. Negative control miRNA and luciferase siRNA duplexes were used as controls. d. 
Tumor growth curves of Du145 stably overexpressing hsa-miR-101 or control vector. 
Data points represent mean tumor volume for five samples infected with vector (red) or 
miR-101 (blue) at the indicated time points.  e. Chromatin immunoprecipitation assay by 
anti-H3K27-me3 demonstrates that hsa-miR-101decreases the binding between EZH2 
and the promoters of its targets, WNT1 and CNR1. Actin is used as a negative control  f. 
Microarray analysis shows that there is a significant overlap, via Fisher’s exact test, 
between SKBr3 cells treated with miR-101 and SKBr3 cells treated with EZH2 siRNA 
regulated genes. The Venn diagram represents the level of overlap for up- and down-
regulated probes in each biological replicates for each experiment. Only those probes that 













Figure 4.4. Genomic aberration in cancer leads to the down regulation of miR-101.  
a. Box plot showing qPCR data for hsa-miR-101, hsa-miR-217 and EZH2 expression in 
benign, prostate cancer (PCA), and metastatic (MET) tumor tissue RNA. b. Heatmap of 
amplification or deletion of mir-101 from aCGH and genomic DNA qPCR. For normal, 
prostate cancer, and metastatic cohorts, there are two rows for the upstream and 
downstream aCGH probe and one row representing the relative quantity (RQ) from 
genomic DNA qPCR. Each column is a different patient sample. A value greater than 0.5 
represents and amplification (red) whereas a value < -0.5 represents a deletion (blue). 
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Through cDNA microarray gene expression profiling of prostate cancer 
specimens, our previous study showed that EZH2 is associated with metastatic prostate 
cancer. In metastatic prostate cancer, EZH2 is upregulated at both the transcript and 
protein levels. By cDNA microarray profiling of samples with EZH2 overexpression or 
knock-down, we demonstrated that EZH2 is a transcriptional repressor which represses 
expression of many tumor suppressors. HDAC activity is required for EZH2 to perform 
its function since the HDAC inhibitor TSA could block EZH2 mediated gene repression. 
Furthermore, we demonstrated that EZH2 is essential for cell proliferation. Another study 
from our group identified that there is an inverse correlation between EZH2 and a tumor 
suppressor E-cadherin in prostate cancer. We found that in EZH2 negative prostate 
samples, E-cadherin expression is high; but in EZH2 positive prostate samples, E-
cadherin expression is repressed.  
In this study, we extended our previous observation in prostate cancer to breast 
cancer, because both prostate and breast cancers are hormone regulated. Here we showed 
for the first time that EZH2 is a biomarker of aggressive breast cancer. By quantitative 
real time PCR and western, we demonstrated that, similar to prostate cancer, EZH2 is 
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upregulated in invasive and metastatic breast cancer at both the transcript and protein 
levels. By tissue microarray (TMA), we showed that EZH2 is mainly expressed in nuclei 
with invasive and metastatic breast carcinomas staining strongly. High EZH2 levels were 
strongly associated with poor clinical outcome in breast cancer patients. A shorter 
disease-free interval after initial surgical treatment, lower overall survival, and a high 
probability of disease-specific death were overserved. Kaplan–Meier analysis showed 
that EZH2 levels were strongly associated with outcome in both ER-positive and -
negative invasive carcinomas suggesting that EZH2 has prognostic utility independent of 
ER status. 
To study the role of EZH2 in breast cancer, we generated adenovirus expressing 
wild-type EZH2 or a dominant negative mutant, EZH2∆SET. Overexpression of EZH2 
promotes anchorage-independent growth in the breast epithelial cell line H16N2 which 
has low endogenous levels of this protein. Furthermore, by three different in vitro or in 
vivo invasion assays, we demonstrated that wild-type EZH2 could increase the invasive 
potential of breast epithelial cells, while the dominant negative mutant, EZH2∆SET could 
not. Importantly EZH2 overexpression could increase HDAC enzymatic activity, and the 
HDAC inhibitors TSA or SAHA could attenuate EZH2 mediated cell invasion.   
In order to illuminate the mechanism by which EZH2 mediates cell invasion 
and cancer progression, we performed cDNA microarray profiling and ChIP-on-chip 
analyses with samples of EZH2 overexpression. Interestingly, among the genes repressed 
by EZH2, several tumor suppressors, including E-cadherin and ADRB2 showed up as the 
targets since they are well-known cell adhesion proteins involved in multiple pathways 
related to cancer progression. In this study, we identified an inverse correlation between 
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EZH2 and E-cadherin in breast cancer tissues and cell lines similar to our observations in 
prostate cancer. Also, we demonstrated that overexpression of EZH2 significantly 
represses E-cadherin expression by qPCR, Northern blot and immunoblot analysis. Co-
expression of E-cadherin to some extent inhibits the invasion induced by EZH2. 
Interestingly, the dominant negative mutant of EZH2, EZH2∆SET could inhibit invasion 
of cancer cell lines. Knock-down of EZH2 by siRNA or shRNA also inhibits invasion of 
cancer cell lines. Most importantly, the cancer cell lines in which EZH2 is stably knock-
down by shRNA were unable to form tumors in nude mice, indicating that EZH2 plays an 
essential role in tumorigenesis. 
Next, in this study we identified dysregulation of microRNAs as a possible 
mechanism of EZH2 upregulation in aggressive breast and prostate cancers.  Among the 
possible microRNAs which are predicted to regulate EZH2 by bioinformatics analysis, 
we showed that only hsa-miR-101 can down-regulate EZH2. In cancer cell lines with low 
endogenous levels of hsa-miR-101 and high EZH2, transfection of the microRNA 
markely repressed EZH2 protein and mRNA levels. Notably, by cDNA microarray 
expression profiling, we showed that there is a significant overlap between genes 
dysregulated by EZH2 siRNA and genes dysregulated by hsa-miR-101 overexpression, 
indicating that hsa-miR-101 may perform a function like siRNA against EZH2 in vivo to 
repress EZH2 expression.  Furthermore, cancer cell lines stably transfected with pre-hsa-
miR-101 or shRNA against EZH2 form smaller tumors or no tumors in mice relative to 
control cells, suggesting that hsa-miR-101could be a potentially promising target for 
cancer therapy.  
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Most importantly, many microRNA profiling studies demonstrated that hsa-
miR-101 is down-regulated in prostate, breast, lung and other cancers. In our prostate 
cancer samples, we showed that there is an inverse correlation between hsa-miR-101 and 
EZH2. By array CGH (comprehensive genomic hybridization) and genomic DNA qPCR, 
we demonstrated that in metastatic prostate and breast cancers, about 30-50% of samples 
which had high EZH2 expression showed deletion or LOH in the genomic region of hsa-
miR-101-1. This finding provides a mechanism for how EZH2 is upregulated during 
cancer progression. 
Taken together, this study showed that EZH2 is a prognostic biomarker of 
aggressive breast cancer and plays an important role during cancer progression. Also this 
study illuminated a novel mechanism by which EZH2 represses the tumor suppressor E-
cadherin and promotes cell invasion. Importantly, this study provides a mechanism by 
which EZH2 is dysregulated during cancer progression by demonstrating that EZH2 is 
promising target for cancer therapy. By repressing EZH2 expression or activity, tumor 














Multiple individuals contributed to the work presented in these chapters and resulting 
manuscripts.  Contributions of individuals for each chapter are as follows: 
 
CHAPTER 2 
Celina Kleer, Qi Cao, Sooryanarayana Varambally and Arul Chinnaiyan 
conceived the experiments and wrote the paper represented in this chapter. Celina Kleer 
performed Tissue microarray. Qi Cao, Ichiro Ota, and Donna Livant performed invasion 
assays. Qi Cao and Sooryanarayana Varambally performed immuno blots. Scott A. 




Qi Cao, Sooryanarayana Varambally and Arul Chinnaiyan conceived the 
experiments and wrote the paper represented in this chapter. Qi Cao performed 
 123
luciferease assays and invasion assays. Qi Cao and Sooryanarayana Varambally 
performed immuno blots. Jindan Yu performed ChIP and ChIP-on-chip assays. 
Sooryanarayana Varambally performed immunofluorescence microscopy. Jindan Yu, 
Saravana Dhanasekaran and Julie Kim performed promoter DNA methylation assays. 
Jindan Yu and Bharathi Laxman generated the stable cell lines and performed the in vivo 
assay. Saravana Dhanasekaran performed northern blots. Scott A. Tomlins performed 
qPCR. Jianjun Yu provided biostatistical support. Xuhong Cao performed cDNA 
microarrays.  Rohit Mehra and Celina Kleer provided breast tissue samples. Jill Granger 
helped revise the manuscript and figures. 
  
CHAPTER 4 
Qi Cao, Sooryanarayana Varambally and Arul Chinnaiyan conceived the 
experiments and wrote the paper represented in this chapter. Qi Cao performed qRT-PCR, 
luciferease assays, cell proliferation assay, and invasion assays. Qi Cao and 
Sooryanarayana Varambally performed immuno blots. Jindan Yu performed ChIP and 
ChIP-on-chip assays. Christopher Maher, Saravana Dhanasekaran and Julie Kim 
analyzed aCGH data. Xuhong Cao performed aCGH and gene expression profiling. 
Bharathi Laxman generated the stable cell lines and performed the in vivo assay. 
Saravana Dhanasekaran performed helped Qi Cao generate 3UTR EZH2 luciferase 
construct.  Chandan Kumar and Sunita Shankar Kumar performed genomic DNA PCR 
 
 
